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The ligand for CD137 is expressed on hematopoietic progenitor cells and antigen-presenting 
cells such as monocytes, dendritic cells and B cells. Reverse signalling of CD137 ligand into 
the cell delivers a potent activating signal that results in the differentiation of hematopoietic 
progenitor cells into macrophages, and monocytes into dendritic cells. CD137 ligand is also 
expressed on acute myeloid leukaemia cells, which characteristically possess a maturation 
block that leads to arrested differentiation and malignancy.  
We hypothesized that CD137 ligand reverse signalling via stimulation with CD137 may also 
induce differentiation of the transformed myeloid cells in acute myeloid leukaemia. Primary 
acute myeloid leukaemia blasts isolated from either the bone marrow or peripheral blood of 
patients at time of diagnosis were stimulated with a recombinant CD137 protein in vitro. 
Reverse signalling through CD137 ligand induced differentiation of these leukemic blasts 
based on morphology, immunophenotype, cellular functions such as phagocytosis and 
proliferation, and cytokine release. These differentiated cells functionally demonstrated a 
more potent T cell co-stimulatory capacity as evidenced by up-regulation of co-stimulatory 
molecules, induction of increased T cell proliferation and cytokine release.  
These results suggest that CD137, as a single factor, is able to induce differentiation of the 
immature blasts in acute myeloid leukaemia into more effective antigen-presenting cells with 
enhanced T cell co-stimulatory potential.  
The ability to overcome the block in myeloid maturation and drive differentiation of acute 
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This thesis focusses the effects of CD137L signalling on acute myeloid leukaemia and its 
potential therapeutic application. The following introduction, therefore, presents an overview 
of CD137 and CD137L biology. Acute myeloid leukaemia and its current state of therapy will 
then be described, followed by a review of some recent studies describing the roles of 
CD137 and CD137L in this particular disease. 
 
1.1 CD137 biology 
1.1.1 The CD137 protein 
CD137, also known as 4-1BB, was originally named “induced by lymphocyte activation” in 
humans and was discovered to be a homologue to 4-1BB in the mouse (Pollok, et al 1993, 
Schwarz, et al 1993). As a type I glycoprotein expressed on the T cell surface, it exists as 
both a 30-kD monomer and a 55-kD dimer. Murine CD137 has a calculated molecular weight 
of 27 kDa and a deduced polypeptide of 256 amino acids (Blobel and Dobberstein 1975), 
the first 23 of which appear to constitute a signal peptide, while amino acids 186-211 
constitute a hydrophobic transmembrane domain. 5 regions in the cytoplasmic domain are 
conserved between mouse and human, suggesting that they are critical for CD137 function 
(Kwon, et al 1989). The molecular weight of the protein backbone of human CD137 is also 
calculated to be 27 kD and contains 255 amino acids. It has features, including the signal 
sequence and transmembrane domain, that indicate that it is a receptor protein. Overall, 
60% of the human CD137 amino acid sequence is identical to that of murine CD137. 
1.1.2 CD137 expression and function 
CD137 is a member of the tumour necrosis factor (TNF) superfamily of receptors (Vinay and 
Kwon 1998) and is expressed on a range of leukocytes. Apart from constitutive expression 
on human monocytes, follicular dendritic cells and CD4+CD25+ regulatory T cells (Broll, et al 
2001, Kienzle and von Kempis 2000, Lindstedt, et al 2003, McHugh, et al 2002, Zheng, et al 
2004), expression of CD137 is inducible and strictly activation-dependent. It is expressed 
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primarily on activated CD4+ and CD8+ T cells (Kwon, et al 1989, Pollok, et al 1993), activated 
dendritic cells and activated NK and NKT cells (Melero, et al 1998). It is not detected on 
resting T cells, but is up-regulated within a few hours upon activation with various agonists, 
and reaches its maximum expression by 24 hours after stimulation (Garni-Wagner, et al 
1996, Kwon, et al 1989, Pollok, et al 1993). 
Although expression of CD137 on human monocytes is difficult to detect (Kienzle and von 
Kempis 2000, Schwarz, et al 1995), stimulation via anti-CD137 antibodies nevertheless up-
regulates TNF-α and IL-8, while down-regulating IL-10. Cross-linking of CD137 on 
CD4+CD25+ regulatory T cells inhibits their immunosuppressive abilities (Choi, et al 2004) 
and CD137 expression on follicular dendritic cells may contribute to co-stimulation of B cells 
(Pauly, et al 2002). Overall, evidence suggests that stimulation of CD137 in these cells 
promotes a pro-inflammatory state. 
The majority of studies on CD137 biology, however, have focussed on its effects in T cells. 
The activation and differentiation of T cells into their effector cells requires two signals –
recognition of a specific antigen by the T cell receptor (TCR) in the context of the 
MHC/antigen complex on the surface of antigen-presenting cells (APCs), and binding of co-
stimulatory molecules on the T cell with their corresponding ligands on the APC (Carreno 
and Collins 2002, Chambers and Allison 1999). The second signal, co-stimulation, is critical 
for modifying and augmenting the subsequent T cell response as it develops. The 
CD80/CD86 and CD28/CTLA-4 receptor-ligand pairs, expressed on APCs and T cells, 
respectively, are the most studied co-stimulatory molecules (June, et al 1990, Lenschow, et 
al 1996, Mueller 2000, Watts and DeBenedette 1999).  
Following initial T cell activation, CD137 is up-regulated and also acts as a co-stimulatory 
molecule, further enhancing T cell responses upon cross-linking by its ligand. While 
signalling through CD137 provides co-stimulatory signals to both CD8+ and CD4+ T cells, 
proliferation and survival of CD8+ T cells is preferentially induced (Shuford, et al 1997, 
Takahashi, et al 1999). CD137-induced survival of CD8+ T cells is mediated by increased 
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expression of bcl-XL and bfl-1, two anti-apoptotic genes, while enhanced proliferation is 
mediated by increased expression of cyclins D and E and degradation of p27kip1, a cell cycle-
dependent kinase inhibitor (Lee, et al 2003a, Lee, et al 2002). CD137 also enhances the 
cytolytic potential of CD8+ T cells via massive induction of IFN-γ and TNF-α (Shuford, et al 
1997, Takahashi, et al 1999), and induces differentiation to CD8+ memory T cells, as 
suggested by up-regulation of the memory CD8+ T cell marker, CD45RO, the CC chemokine 
receptor 6 and the contents of granzyme B (Kim, et al 2002). 
By comparison, studies on the effects of CD137 signalling in CD4+ T cells have been limited 
and inconsistent. Similar to CD8+ T cells, CD137 expression is increased upon activation of 
CD4+ T cells, though overall expression is lower compared to CD8+ T cells (Taraban, et al 
2002). Several studies have demonstrated that CD137 signalling is immunostimulatory in 
CD4+ T cells. It induces IL-2 secretion (Gramaglia, et al 2000) and inhibits activation-induced 
cell death (Hurtado, et al 1997). DO11.10 TCR transgenic CD4+ T cells, which are CD137-
deficient, possess reduced proliferative capacity and are more sensitive to activation-
induced cell death when exposed to antigen in vitro (Lee, et al 2003b). Similarly, transgenic 
CD4+ T cells that constitutively express CD137 demonstrate extensive expansion and 
reduced apoptosis compared to normal T cells (Kim, et al 2003). Also, in vivo administration 
of anti-CD137 antibodies into aged mice can stimulate and restore the otherwise deficient T 
cell response. In vitro studies confirmed that this rescue was mediated by CD137 signalling 
in CD4+ T cells (Bansal-Pakala and Croft 2002). 
Conflicting studies suggest that CD137 plays an immunosuppressive role in CD4+ T cells. 
Rather than protect against apoptosis, CD137 signalling increases activation-induced cell 
death in a model of graft-versus-host disease (Kim, et al 2005). In vivo delivery of anti-
CD137 antibodies induces CD4+ T cell anergy, resulting in suppression of humoral 
responses (Mittler, et al 1999). Additionally, CD137 indirectly mediates the depletion of 
antigen-specific CD4+ T cells in autoimmune disease models by promoting the differentiation 
of CD8+ T cells to CD8+CD11c+ T cells (Seo, et al 2004), and induces the expansion of 
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immunosuppressive CD4+CD25+ regulatory T cells (Zheng, et al 2004) – findings which 
directly contradict a study by Choi et al (Choi, et al 2004). 
1.1.3 Dual roles of CD137 signalling in anti-tumour immunity and autoimmune 
disease 
Although these inconsistencies have yet to be fully resolved, taken together, they do point 
toward a dual nature of CD137 signalling. Somewhat paradoxically, CD137 is both able to 
effectively enhance anti-tumour immunity and attenuate unwanted autoimmune responses. 
Monoclonal anti-CD137 antibodies administered in vivo in a mouse model of mastocytoma 
results in rejection of even established tumours, compared to rapid tumour progression in 
the control groups (Shuford, et al 1997). The presence of infiltrating CD4+ and CD8+ T cells, 
as well as macrophages, was clearly apparent in shrinking tumours that had been surgically 
removed for analysis. A subsequent study also showed that tumour-specific cytotoxic T cell 
activity was enhanced in the spleen of the treated mice (Melero, et al 1997). In this 
mastocytoma model, both CD4+ and CD8+ T cells, as well as NK cells are critical for tumour 
rejection, as selective depletion of any of these populations resulted in complete abrogation 
of the anti-tumour effect (Melero, et al 1998, Melero, et al 1997). While anti-CD137 
monoclonal antibodies are unable to illicit T cell-mediated responses against poorly 
immunogenic tumours, breaking of this immunological ignorance or tolerance (via 
immunization with tumour-derived peptides) subsequently allows the anti-CD137 antibodies 
to stimulate a cytotoxic T cell response that results in regression of established tumours 
(Wilcox, et al 2002). Repeated stimulation of anergic tumour-specific T cells with anti-CD137 
antibodies has even been shown to reverse the T cell anergy, allowing the resumption of a T 
cell-mediated anti-tumour response (Wilcox, et al 2004). 
These pro-inflammatory effects suggest that CD137 would further aggravate autoimmune 
responses in cases of autoimmune disease. However, several studies have demonstrated 
that the reverse is true. Administration of agonistic anti-CD137 monoclonal antibodies results 
in amelioration of disease in several autoimmune disorders including experimental 
 6 
 
autoimmune encephalitis (Sun, et al 2002), systemic lupus erythematosus (Foell, et al 2003), 
rheumatoid arthritis (Seo, et al 2004) and chronic graft-versus-host disease (Kim, et al 
2005). The disease mechanisms in many autoimmune disorders are often driven by auto-
reactive CD4+ T cells that secrete pro-inflammatory cytokines, activate macrophages and 
stimulate B cells to produce auto-reactive antibodies. The therapeutic effects of agonistic 
anti-CD137 antibodies may therefore be mediated by an inhibition of auto-reactive CD4+ T 
cell function, such as IL-2 and IL-4 secretion (Foell, et al 2003), and induction of apoptosis 
(Kim, et al 2005, Sun, et al 2002). In a chronic graft-versus-host disease model, anti-CD137 
antibodies were also shown to indirectly induce apoptosis of auto-reactive B cells (Kim, et al 
2005), possibly via the activation of CD137-expressing monocytes which are able to induce 
B cell apoptosis (Kienzle and von Kempis 2000). An indirect, CD8+CD11c+ T cell-mediated 
mechanism of CD4+ T cell depletion was also demonstrated by Seo et al. Engagement of 
CD137 on CD8+ T cells in a collagen-induced rheumatoid arthritis model induced 
differentiation to CD8+CD11c+ T cells, which activated antigen-presenting cells via secretion 
of IFN-γ, ultimately leading to the killing of adjacent collagen-specific CD4+ T cells (Seo, et al 
2004).  
In summary, CD137 appears to play dual roles in anti-tumour immunity and autoimmune 
disease. It induces potent immunostimulatory responses, particularly in CD8+ T cells, 
resulting in increased proliferation, survival and cytolytic activity that leads to eradication of 
even established tumours, while also attenuating the self-reactive, CD4+ T cell-mediated 
pathology characteristic of several autoimmune diseases.  
 
1.2 CD137L biology 
1.2.1 The CD137L protein 
The ligand for CD137, CD137L, is a member of the TNF superfamily of proteins (Armitage 
1994). It is a 34 kD type II transmembrane glycoprotein (Goodwin, et al 1993) that likely 
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exists as a 97 kD disulphide-linked homodimer. The CD137L polypeptide is 254 amino acids 
long in humans and 309 amino acids long in mouse, though only 36% sequence homology is 
observed (Alderson, et al 1994). Apart from CD137, CD137L has also been shown to 
interact with several toll-like receptors in a murine system, including TLR3, TLR4 and TLR9 
expressed on macrophages, resulting in induction of pro-inflammatory cytokines (Kang, et al 
2007). 
1.2.2 CD137L expression 
CD137L is expressed constitutively on all antigen-presenting cells. It is expressed on 
monocytes, macrophages and dendritic cells (Futagawa, et al 2002, Laderach, et al 2003, 
Pollok, et al 1994), albeit at low levels. Activation or further maturation of these cells with 
pro-inflammatory stimuli, such as lipopolysaccharide (LPS) or anti-CD40 antibodies, is able 
to up-regulate expression (Futagawa, et al 2002, Laderach, et al 2003). It is also 
constitutively expressed on mature B cells and activated B cells (Pollok, et al 1994). Like 
CD137, low levels of CD137L are inducible on T cells, with expression being strictly 
activation-dependent (Goodwin, et al 1993, Polte, et al 2007). 
1.2.3 Bi-directional signalling of CD137/CD137L 
CD137L exerts its effects on CD137-expressing cells, like activated T cells, via engagement 
of CD137, leading to signal transduction. However, upon interaction with CD137, CD137L is 
also able to initiate a signal into the ligand-expressing cell – a phenomenon known as 
reverse signalling. The CD137/CD137L system is therefore capable of bi-directional 
signalling, an ability which it shares with many other members of the TNF receptor and TNF 
families (Eissner, et al 2004) and which is made possible because most proteins of this 
superfamily are expressed as transmembrane proteins possessing cytoplasmic domains 
(Gravestein and Borst 1998). Compared to CD137 signalling, less is currently known about 
the effects of CD137L signalling into the cells on which it is expressed. 
1.2.4 CD137L signalling in monocytes 
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Cross-linking of CD137L on the monocyte cell surface by recombinant CD137 protein or 
anti-CD137L antibody results in increased adherence within just a few hours (Langstein and 
Schwarz 1999), secretion of pro-inflammatory cytokines such as TNF-α, IL-6 and IL-8 and 
inhibition of anti-inflammatory cytokines such as IL-10 (Laderach, et al 2003, Langstein, et al 
1998). This demonstrates that signalling through CD137L alone is sufficient for monocyte 
activation. However, cross-linking of CD137L by an immobilized form of CD137 or anti-
CD137L antibody is essential, as soluble CD137 has no effect on monocytes. The extent of 
monocyte activation is also dose-dependent, with higher concentrations of recombinant 
CD137 inducing higher levels of IL-8 secretion (Langstein, et al 1998). CD137L signalling 
also promotes monocyte survival, an effect mediated by the release of the cytokine, 
macrophage colony-stimulating factor (M-CSF), a potent survival factor for monocytes. 
Unexpectedly, CD137L signalling also increases the rate of apoptosis in activated 
monocytes, as evidenced by higher amounts of fragmented DNA. A concomitant increase in 
proliferation rate was also observed. As the cells did not increase in number but did increase 
in size and became multi-nucleated, the monocytes had likely undergone endomitosis 
(Langstein and Schwarz 1999). The monocyte population ultimately expanded, as the 
increased proliferation more than compensated for the CD137-induced apoptosis.  
Although CD137 is not as potent as LPS at activating monocytes, it can further stimulate 
cytokine release by monocytes that have already been maximally activated by LPS, 
demonstrating synergy (Langstein, et al 2000). 
1.2.5 CD137L signalling in dendritic cells 
The effects of CD137L signalling in dendritic cells (DCs) are very similar to those observed 
in monocytes. Increased adherence and secretion of IL-6 and IL-12 are observed, as well as 
up-regulation of CD11c, CD80, CD86 and MHC class II (Futagawa 2002, kim 2002, 
langstein 1999) demonstrates that CD137 is able to induce further maturation of DCs. TNF-
α, released by DCs upon stimulation with CD137, is essential for this maturation, as blocking 
with anti-TNF-α antibodies prevented further DC maturation (Lippert 2008). 
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1.2.6 CD137L signalling in B cells 
Studies on CD137L signalling in B cells have produced somewhat conflicting results. While 
CD137L is expressed on B cells, whether this expression is induced or constitutive is unclear 
(Jung, et al 2004, Zhou, et al 1995). In a transgenic mouse model, constitutive expression of 
CD137L on APCs resulted in gradual depletion of peripheral B cells over time (Zhu, et al 
2001). This could be due to over-stimulation of the B cells, as prolonged signalling through 
the constitutively expressed CD137L can lead to activation-induced cell death and studies 
have demonstrated that CD137L signalling in pre-activated B cells enhances proliferation 
and immunoglobulin synthesis (Pauly, et al 2002). As interaction between CD137 expressed 
on monocytes and CD137L expressed on B cells has been shown to induce B cell apoptosis 
(Kienzle and von Kempis 2000), it is also possible that activated T cells, which express 
CD137, may become over-stimulated by the CD137L-expressing B cells, leading to B cell 
elimination. CD137-CD137L interactions also likely play important roles in regulating 
maturation and activation of B cells (Pauly, et al 2002). 
1.2.7 CD137L signalling in T cells 
CD137L is not expressed on primary T cells, or constitutively expressed at very low levels 
(Pollok, et al 1994, Salih, et al 2000). It may be possible that expression levels of CD137L on 
T cells is so low that detection via flow cytometry or other commonly used methods is not 
possible. Unlike the activating abilities of CD137L signalling in APCs, or the co-stimulating 
abilities of CD137 on T cells, CD137L signalling in T cell lines appears to be inhibitory. Co-
culture of CD137-expressing transfected CHO cells with anti-CD3-activated human 
peripheral blood mononuclear cells (PBMCs) results in complete inhibition of T cell 
proliferation and induction of apoptosis (Schwarz, et al 1996). A similar response is observed 
when T cells are treated with anti-CD137L antibodies (Ju, et al 2003). Very little is known 
about the underlying mechanisms by which CD137L signalling suppresses T cell function, 
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although a study has demonstrated that CD137L-mediated T cell apoptosis is independent 
of CD95 (Michel, et al 1999). 
 
1.3 Influence of CD137L signalling on myelopoiesis  
1.3.1 Myelopoiesis and myeloid cells 
All white blood cells are derived from the haematopoietic stem cells (HSCs) found in the 
bone marrow. Being undifferentiated and pluripotent, HSCs have the ability to differentiate 
into any cell of the lymphoid or myeloid lineage of white blood cells, thereby replenishing or 
increasing the size of the relevant cell population in peripheral circulation. HSCs are also 
self-renewing, though their proliferative capacity and potential for differentiation into various 
cell types is progressively lost as they commit to a specific lineage, eventually resulting in 
terminal differentiation to a mature, functional and distinct cell. Myelopoiesis is the process of 
HSC commitment to the myeloid lineage and differentiation into myeloid cells, which include 
neutrophils, eosinophils, basophils (the granulocytes), monocytes, macrophages and 
myeloid dendritic cells.  
Peripheral monocytes circulate in the blood and migrate into tissues where they differentiate, 
depending on signals from the local micro-environment, into either macrophages or DCs. 
Macrophages are phagocytic cells of the innate immune system and are resident in almost 
all tissues. They have critical roles in a wide range of functions that include host defence 
against pathogens, maintaining homeostasis, scavenging of apoptotic or harmful compounds 
and wound healing. Macrophages are therefore not a homogenous population of cells and 
are further classified according to their phenotype and functions (Martinez, et al 2008). The 
pro-inflammatory M1 macrophages are activated by pro-inflammatory stimuli such as IFN-γ, 
TNF-α and LPS and promote IL-12-mediated Th1 responses (Verreck, et al 2004). Their 
primary role is in host defence and pathogen clearance, and as such, they secrete high 
levels of pro-inflammatory cytokines and also possess a high capacity for killing 
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phagocytosed pathogens via the production of superoxide anions and reactive oxygen 
species (Bonnotte, et al 2001, Mytar, et al 1999). M2 macrophages, on the other hand, 
appear to play anti-inflammatory roles and are important for attenuating and resolution of an 
inflammatory response. In contrast to M1 macrophages, they secrete low levels of IL-12 and 
high levels of the anti-inflammatory cytokine, IL-10, and generally promote Th2 responses 
(Anderson, et al 2002). Macrophages found within a tumour microenvironment are often 
polarized towards this M2 phenotype. The presence of such tumour-associated 
macrophages confers a survival benefit to the tumour and facilitates growth, angiogenesis 
and metastasis (Mantovani, et al 2002), as the M2 phenotype normally possesses tissue 
remodelling and wound healing functions (Kodelja, et al 1997, Song, et al 2002). Despite 
their classification into distinct subtypes, macrophages tend to exhibit characteristics from 
both M1 and M2 phenotypes and therefore lie along a spectrum while being polarized more 
towards one end than the other, depending on the macrophage functions (Mosser and 
Edwards 2008). 
Myeloid dendritic cells are the most abundant type of DC and are also derived from 
monocytes. Plasmacytoid DCs are a much rarer sub-population of DCs, derived instead from 
lymphoid progenitors, and will not be discussed here. DCs are antigen-presenting cells. Like 
macrophages, they are also phagocytic, but unlike macrophages, their primary function is 
not pathogen destruction or clearance. Rather, DCs process and present antigens to T cells 
and serve to initiate antigen-specific adaptive immune responses. Immature DCs possess a 
high capacity for capture and processing of antigen but are poor stimulators of a T cell 
response (Banchereau and Steinman 1998). Pro-inflammatory signals then induce 
maturation of these DCs; potential for antigen capture is decreased while several T cell co-
stimulatory molecules, including CD80 and CD86, and expression of MHC-peptide 
complexes are up-regulated (Caux, et al 1994). Pro-inflammatory cytokines, including IL-12, 
IL-8 and MIP-1α are also secreted (Cella, et al 1996, Koch, et al 1996). Mature DCs are then 
the most potent of the antigen-presenting cells, being the only APC capable of activating 
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naïve T cells, and effectively stimulate T cells to initiate an antigen-specific adaptive immune 
response (Banchereau and Steinman 1998). 
Granulocytes are the most abundant of circulating white blood cells and, compared to 
macrophages and DCs, are relatively short-lived. Neutrophils are by far the most abundant 
type of granulocyte and are highly phagocytic and effective at eliminating pathogens via 
secretion of degrading enzymes and reactive oxygen species. Basophils and eosinophils are 
less abundant, and are involved in host defence against parasites that are too large for 
phagocytosis, and are also negatively implicated in allergic reactions. Production of 
granulocytes from pre-cursor cells in the bone marrow is increased during infections, as they 
are required in higher numbers during inflammatory processes and also because their 
numbers in general circulation need to be replenished after massive extravasation into 
tissues (Hickey and Kubes 2009, Hirai, et al 2006). 
1.3.2 CD137L signalling and myelopoiesis 
CD137L signalling has been found to drive myelopoiesis in several myeloid cell types. When 
murine lineage-CD117+ haematopoietic progenitor cells, derived from bone marrow, were 
treated with recombinant CD137, the cells displayed obvious morphological changes, 
adopting flattened, spindle-shaped morphologies and became more adherent. Expression of 
the myeloid marker, CD11b, the monocyte marker, CD14, the macrophage marker, F4/80 
and the DC marker, CD11c, was up-regulated. These cells possessed greatly enhanced 
phagocytic capacity and IL-10 secretion, but did not produce IL-12 and were unable to 
stimulate T cell proliferation in an allogeneic mixed lymphocyte reaction (MLR) (Jiang, et al 
2008a). A similar study examining CD137L signalling in human CD34+ cells derived from 
cord blood yielded very similar results. Expression of macrophage markers like CD11b and 
CD14 were enhanced in CD137-treated CD34+ cells, as was phagocytosis and IL-10 
production, while IL-12 was suppressed and DC markers could not be detected (Jiang, et al 
2008b). Taken together, these observations demonstrate that CD137L signalling induces 
monocytic differentiation of haematopoietic progenitor cells to macrophages, but not 
 13 
 
dendritic cells. Although comprehensive studies are limited, CD137L signalling does not 
appear to induce differentiation of progenitor cells to granulocytes (Jiang, et al 2008a, Jiang 
and Schwarz 2010). 
CD137L signalling also induces differentiation of human peripheral blood monocytes to 
dendritic cells in vitro. Monocytes treated with recombinant CD137 adopted characteristic 
DC morphology, up-regulated co-stimulatory molecules such as CD80 and CD86, up-
regulated the DC marker, CD83, lost CD14 expression and exhibited lower phagocytic ability 
compared to control cells (Kwajah and Schwarz 2010). Importantly, these CD137-generated 
DCs were even more potent at stimulating T cells in an allogeneic MLR than were classical 
DCs (i.e. DCs generated from monocytes using GM-CSF and IL-4). T cells co-cultured with 
CD137-generated DCs demonstrated higher proliferation and higher production of the pro-
inflammatory cytokines IFN-γ, IL-13 and IL-17 than T cells cultured with classical DCs. 
CD137-generated DCs are also distinct from classical DCs in several other respects. They 
do not secrete IL-12 (Ju, et al 2009) or IL-23 (Kwajah and Schwarz 2010) as classical DCs 
do, and do not express characteristic DC markers such as CD1a or DC-SIGN. In addition to 
driving differentiation of monocytes to DCs, CD137L signalling also induces maturation of 
immature DCs. CD137-matured DCs are similarly more potent than classically-matured DCs 
and are capable of stimulating stronger Th1 responses in autologous T cells (Lippert, et al 
2008). CD137L signalling also enhances the migratory potential of monocytes in vitro 
(Drenkard, et al 2007) and up-regulates CXCL4 and CCR7, chemokine receptors that 
influence DC migration, in DCs (Kwajah and Schwarz 2010, Lippert, et al 2008). 
 
1.4 Trogocytosis 
A study by Ho et al (Ho, et al 2013) has demonstrated that CD137 can be transferred from 
the surface membrane of CD137-expressing cells to CD137L-expressing cells, via a process 
known as trogocytosis. This process allows the rapid intercellular transfer of intact cell-
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surface proteins between cells that are in contact with one another (Joly and Hudrisier 
2003). Although the exact mechanisms by which this transfer occurs is unknown, there is 
strong evidence to suggest that it involves an uprooting and transfer of the intact surface 
protein along with a membrane fragment from one cell to the other. Various observations, 
such as the detection of both extracellular and intracellular domains of transferred 
transmembrane proteins (Carlin, et al 2001, Huang, et al 1999, Vanherberghen, et al 2004) 
and the transfer of lipophilic fluorophore to recipient cells (Patel and Mannie 2001, 
Stinchcombe, et al 2001, Tabiasco, et al 2002) are consistent with this idea.  
The functional significance of such intercellular protein transfer depends largely on the 
specific protein and cell types involved. Membrane-bound antigens can be transferred on to 
the surface of B cells and subsequently internalized, leading to presentation of the 
transferred antigen by MHC class II protein to T cells (Batista, et al 2001, Fleire, et al 2006). 
DCs can also acquire antigen upon contact with other cells bearing antigen-MHC class I 
complexes, via intercellular transfer, and subsequently cross-present the antigen to CD8+ T 
cells (Russo, et al 2000). Transfer of co-stimulatory molecules such as CD80, and peptide-
MHC class II complexes, from APCs to CD4+ T cells confers antigen-presenting capabilities 
to these cells and allows them to activate and induce proliferation of neighbouring CD4+ T 
cells (Zhou, et al 2005). These observations demonstrate that trogocytosis can result in the 
stimulation and amplification of an immune response. However, attenuation of the immune 
response can also occur. Transfer of peptide-MHC class I complexes from APCs to cytotoxic 
T cells results in the killing of these T cells by neighbouring antigen-specific cytotoxic T cells 
(Huang, et al 1999), thereby limiting T cell responses. Additionally, transfer of a ligand to an 
effector cell may result in down-regulation or internalization of the corresponding receptor in 
the neighbouring effector cells. Indeed, CD137L is internalized upon binding and transfer of 
CD137 to CD137L-bearing recipient B cells and Hodgkin Reed-Sternberg (HRS) cells – 
malignant B cells found in Hodgkin’s Lymphoma. This effectively down-regulates surface 
CD137L expression, resulting in impaired T cell activation and allowing the malignant B cells 
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to circumvent the co-stimulatory effects that CD137L expression normally confers (Ho, et al 
2013).  
 
1.5 Activity of soluble and immobilized CD137 
Various members of the TNF family of receptors require cross-linking and oligomerization by 
their respective ligands in order for signal transduction to occur. While the soluble ligands 
are unable to illicit any response, oligomerization and stabilization by an immobilized form of 
the ligand greatly enhances the effects of receptor signalling (Aoki, et al 2001, Schneider, et 
al 1998, Wyzgol, et al 2009). In common with other members of the TNF family of receptors, 
recombinant CD137 protein is only able to cross-link CD137L and induce signalling into the 
CD137L-expressing cell when it is immobilized; soluble CD137 or anti-CD137L antibody is 
unable to induce any effect in CD137L-bearing cells (Langstein, et al 1998, Schwarz, et al 
1996).  
Several methods for immobilization of recombinant CD137 protein have been used in vitro, 
including coating on to the surface of culture plates and immunological cross-linking with 
anti-Fc antibody (Langstein, et al 1998), and oligomerization of FLAG-tagged proteins using 
anti-FLAG antibody (Wyzgol, et al 2009). However, an effective and practical method of 
administering immobilized recombinant CD137 for in vivo applications has yet to be 
developed. 
 
1.6 Acute myeloid leukaemia 
Acute myeloid leukaemia (AML) is a cancer of the myeloid lineage of white blood cells, 
characterized by arrested myelopoiesis and over-proliferation of clonal, neoplastic cells, 
leading to the accumulation of immature, non-functional myeloid cells in the bone marrow 
and/or blood (Stone, et al 2004). As myelopoiesis is impaired and normal bone marrow is 
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gradually replaced with malignant cells, AML patients typically present with symptoms 
indicative of bone marrow failure. Bone pain, fever, fatigue, bruising, bleeding and increased 
risk of infection are commonly observed as a consequence of decreased numbers of red 
blood cells, platelets and functional myeloid cells (Webb 2010). 
1.6.1 Classification and subtypes of AML 
The first system used to comprehensively classify AML was the French-American-British 
(FAB) system (Bennett, et al 1976). This scheme requires at least 30% leukemic blasts to be 
present in the bone marrow for a diagnosis of AML, and distinguishes several subtypes 
according to the myeloid cell and stage of development at which differentiation is arrested. 
The M0 subtype is classified as undifferentiated myeloblastic leukaemia, where the term 
“myeloblast” refers generally to immature blasts of the myeloid lineage, as opposed to 
granulocytic pre-cursor cells (which are also referred to as myeloblasts in literature). 
Subtypes M1 and M2 are acute myeloblastic leukaemia without and with some degree of 
maturation, respectively. M3 is acute promyelocytic leukaemia (APL), a distinct subtype in 
which the AML cells are derived from granulocytic pre-cursor cells. M4 and M5 are acute 
myelomonocytic leukaemia and acute monocytic leukaemia, respectively, and consist of an 
increasing proportion of leukaemic pro-monocytic or monocytic cells. Subtypes M6 and M7 
are acute erythroblastic leukaemia and acute megakaryoblastic leukaemia, respectively. Due 
to the cytogenetic and molecular heterogeneity of AML, the usefulness of the FAB 
classification system has proven rather limited. More recently, the World Health Organization 
(WHO) has incorporated additional cytogenetic and mutational analyses into the 
classification system, resulting in better distinction between individual AML cases and useful 
prognostic information (Harris, et al 2000).  
The mutational status of three oncogenes, in particular, are routinely examined when 
providing a diagnosis for AML. The NPM1 gene codes for a nucleolar phospho-protein that, 
when mutated, contributes to a maturation block characteristic of the leukaemic cells. This 
gene is mutated in approximately 30% of adult AML cases, of which 85% display normal 
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karyotype (Falini, et al 2007). Mutation results in increased export from the nucleus and 
aberrant accumulation in the cytoplasm, which is detectable by immunostaining. AML cells 
with NPM1 mutations tend to be more mature, being negative for the haematopoietic 
progenitor cell marker CD34 and exhibiting monocytic morphology (Pasqualucci, et al 2006). 
The FLT3 gene codes for the fms-like tyrosine kinase and is mutated in 25-45% of AML 
cases at differing frequencies across all karyotypes. Mutation of FLT3, usually via internal 
tandem duplication of the juxtamembrane domain (FLT3-ITD) or in the tyrosine kinase 
domain (FLT3-TKD), results in constitutive activation of the tyrosine kinase and 
hyperproliferation of the leukaemic cells (Kussick, et al 2004, Reilly 2003). Simultaneous 
mutations in both FLT3 and NPM1 can occur in AML. 
The CEBPA gene codes for a transcription factor involved in cell cycle progression and 
maturation of granulocytic cells (Ghanem, et al 2012, Leroy, et al 2005); mutation of this 
gene results in arrest of myeloid cell maturation. It is mutated in 5-10% of AML cases, most 
of which also have normal karyotype (Marcucci, et al 2008). Mutations in CEBPA do not 
occur together with mutations in NPM1, and are only rarely occurs with mutations in FLT3 
(Green, et al 2010). 
Comprehensive diagnosis of AML therefore includes morphological, immunophenotypic, 
cytogenetic and molecular analyses. 
1.6.2 Patient prognosis and AML classification 
Certain AML subtypes, karyotypes and/or mutations have prognostic significance for AML 
patients. The cytogenetic abnormality, t(8;21), is observed in 5-10% of all AML cases and 
involves a translocation that fuses the AML1 gene on chromosome 21 with the ETO gene on 
chromosome 8 (Arber, et al 2003, Grimwade, et al 1998). As the AML1 gene normally codes 
for a subunit of the heterodimeric core-binding factor (CBF) haematopoietic transcription 
factor, the resulting AML1/ETO fusion oncoprotein interferes with various CBF-mediated 
signalling pathways, resulting in abnormal proliferation and impaired myelopoiesis (Elagib 
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and Goldfarb 2007)(WHO 2008). Another cytogenetic abnormality which disrupts CBF-
mediated signalling is inv(16), an inversion of chromosome 16 that produces the fusion 
protein CBF/MYH11. Both of these karyotypes have comparatively favourable prognoses 
(Cheng, et al 2009, Grimwade, et al 2010), with higher rates of complete remission, lower 
rates of relapse and better overall survival. Although CBF-leukaemias are currently not 
treated with any targeted therapies, the CBF pathway is being investigated for potential anti-
leukaemia targets (Hasserjian 2013). AML patients with mutations in NPM1 but not FLT3-
ITD mutations have similarly favourable prognosis, as do patients with bialleleic CEBPA 
mutations (Dufour, et al 2010, Renneville, et al 2008, Schlenk, et al 2008) 
Several cytogenetic profiles are associated with poorer prognosis. Patients with deletion of 
one copy of chromosome 7 (monosomy 7), deletion or abnormalities in the long arm of 
chromosome 5 (5q) and/or chromosome 3 (3q) have lower chances of complete remission, 
higher risk of relapse and less than 50% overall survival. Patients with the t(9;22) 
translocation, which results in a constitutively active tyrosine kinase coded for by the fusion 
gene BCR-ABL and which contributes to un-regulated myeloid cell proliferation, also carry 
an adverse prognosis (Grimwade, et al 1998)(Webb 2010). Cases with FLT3-ITD mutations 
are also unfavourable, and even adversely affect the prognosis of otherwise favourable 
NPM1-mutated AML (Renneville, et al 2008). Complex karyotypes which contain more than 
three concurrent cytogenetic abnormalities also have poor outcomes.  
One distinct subtype of AML has particularly well-defined mutational characteristics and 
prognosis. 95% of cases of acute promyelocytic leukaemia, which is FAB subtype M3, 
possess the t(15;17) translocation. This translocation produces the PML/RAR fusion protein, 
which strongly represses transcription of genes involved in promyelocyte differentiation. 
Physiological concentrations of retinoic acid normally relieve the transcriptional repression of 
the RAR protein, allowing differentiation to occur, but the PML/RAR fusion protein is 
resistant to such concentrations (Wang and Chen 2008). This block in maturation can be 
overcome, however, by all-trans retinoic acid (ATRA), leading to terminal differentiation of 
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the APL cells to neutrophils. Additionally, arsenic trioxide (ATO) has been found to degrade 
the PML/RAR fusion protein and induce apoptosis of APL cells in patients that have relapsed 
after initial ATRA treatment (Douer and Tallman 2005). Due to the efficacy of the 
combination treatment of ATRA/ATO in patients carrying the t(15;17) translocation, 
prognosis and long term survival is excellent and most APL patients are essentially curable 
(Hasserjian 2013, Wang and Chen 2008). Even concurrent FLT-ITD mutations, which are 
generally unfavourable, do not adversely affect the prognosis of t(15;17) APL patients 
(Grimwade, et al 2010). 
1.6.3 Runx1 and Cbfb murine models of AML 
Although many studies have been performed in vitro on primary human AML cells, very few 
mouse models of AML currently exist. One of the major difficulties in developing a suitable 
mouse model is that AML is not caused by the dysfunction of only a single gene; none of the 
current models are ideal. 
The core binding factor (CBF) transcription complex, consisting of the subunits RUNX1 and 
CBFβ, is a key regulator of normal haematopoiesis. Mutations in either subunit leading to 
loss of function have been reported at high frequencies in patients with myeloproliferative 
disorders, acute leukaemias (including AML), and also predisposes patients to the 
development of AML (Imai, et al 2000, Osato, et al 1999, Song, et al 1999). Mutation of the 
Runx1 gene is commonly observed in AML patients carrying the t(8;21) translocation, while 
mutation of Cbfb by inversion of chromosome 16 is highly associated with acute 
myelomonocytic leukaemia (Cao, et al 1997, Castilla, et al 1999). 
In mice, inactivation of Runx1 or Cbfb impairs haematopoiesis, leading to differentiation 
blocks across all lineages (Castilla, et al 1996, Okuda, et al 1996, Wang, et al 1996). 
However, the use of Runx1-/- or Cbfb-/- mouse models for the study of AML is made difficult 
because these mutations are embryonically lethal. Several newer approaches sought to 
bypass this lethality by employing the Cre/loxP system in transgenic Runx1 or Cbfb 
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conditional knock-out mice. These mice, while developing normally, possessed only subtle 
haematopoietic defects and did not display characteristics of full blown AML (Fenske, et al 
2004, Higuchi, et al 2002). This reflects the insufficiency of a single genetic mutation to 
cause AML, while the complexity of these transgenic models makes introduction of 
additional, cooperating mutations difficult. Although no ideal mouse model of AML exists, 
current models are nevertheless very important for investigating potential therapies. 
 
1.6.4 Emerging therapies in AML 
Currently, the widely accepted approach to AML treatment is based on a course of induction 
chemotherapy which aims to initially destroy both healthy and malignant haematopoietic 
cells in the bone marrow and then allow recovery and repopulation by healthy cells, thereby 
inducing complete remission (less than 5% blasts in bone marrow) (Stone, et al 2004). 
Combinations of several agents, such as cytarabine and anthracycline, induce CR in 60-80% 
of patients, while 50-70% of these patients are expected to relapse within 3 years 
(Lowenberg, et al 2003, Tallman, et al 2005). The high chance of disease recurrence and 
unsuitability of inductive chemotherapy in older patients necessitates novel approaches to 
AML therapy. 
One novel approach has been the targeted delivery of cytotoxic agents to AML cells. 
Gemtuzumab ozogamicin (OG) consists of a monoclonal anti-CD33 antibody conjugated to 
calicheamicin, a potent cytotoxic agent. The antibody binds to CD33, which is expressed on 
the majority of AML cells, and is then internalized along with the conjugated toxin and 
causes double-stranded DNA breakage and apoptosis (Stasi, et al 2008). A second anti-
CD33 antibody-mediated approach is Lintuzumab, which utilizes complement-dependent 
and antibody-directed cellular cytotoxicity to induce AML cell apoptosis (Vitale, et al 1999). 
Multi-drug resistance in AML contributes to lower chemotherapy-induced remission rates 
and higher risk of relapse. The use of several multi-drug-resistant modulators have been 
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examined in combination with conventional chemotherapeutic agents to potentially achieve 
more favourable CR and relapse rates, by inhibiting the elements responsible for multi-drug 
resistance. P-glycoprotein is one such protein and is over-expressed in multi-drug resistant 
AML (Wilson, et al 2006). Expressed on the cell membrane, it acts as a pump to remove 
chemotherapeutic agents from within the AML cell. Selective inhibitors that bind with high 
affinity to P-glycoprotein and block its effects are in development (Dantzig, et al 1996, Sato, 
et al 1991). 
Because mutations in FLT3 occur in such a high proportion of AML, several agents that 
target FLT3 and aim to inhibit its pro-survival and hyper-proliferative effects are in 
development. Studies indicate that these FLT3-inhibitors appear to preferentially kill AML 
cells with FLT-ITD mutations, induce remission in the majority of patients, inhibit AML cell 
proliferation and have relatively mild side effects, such as muscle weakness and fatigue 
(Brown, et al 2004, DeAngelo, et al 2006, Stone, et al 2005). Taken together, these studies 
suggest that FLT3-inhibitors are a promising avenue for the treatment of AML. 
These potential therapies, among others, have demonstrated varying levels of efficacy in 
clinical trials (Robak and Wierzbowska 2009, Tallman 2006); it remains to be seen if any will 
have a significant impact on the state of AML treatment. 
1.6.5 Immunotherapy of AML 
Utilizing and augmenting the host immune system to mount an anti-cancer response has 
recently proven to be a very promising and powerful approach to anti-cancer therapy, and 
many forms of immunotherapy are currently being investigated to provide a more effective 
way of eradicating leukaemic stem cells and minimal residual disease. 
Monoclonal antibodies directed against immunosuppressive molecules, such as CTLA-4, 
PD-1 or PD-L1/PD-L2, are able to remove the anti-inflammatory effects mediated by these 
molecules and subvert some of the mechanisms by which AML evades the immune system. 
Blocking of CTLA-4 results in enhanced T cell stimulation by leukaemia-derived DCs in vitro 
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(Zhong, et al 2006), while blocking of PD-L1 expressed on the leukaemic cells in a mouse 
model of AML promoted tumour rejection and survival (Zhang, et al 2009). 
Another immunotherapeutic approach is the vaccination of AML patients with modified AML 
cells that will be able to more effectively present a wider and more representative array of 
leukaemic antigens to the host immune system. A study utilized lentiviral transduction of 
primary AML cells to up-regulate the co-stimulatory molecule CD80 and IL-2 secretion, 
leading to the in vitro enhancement of NK cell cytotoxicity, T cell proliferation, induction of a 
Th1 response and resulting ultimately in increased AML cell death (Hardwick, et al 2010, 
Ingram, et al 2009). Another strategy has been to use differentiating agents and cytokine 
cocktails to induce in vitro differentiation of AML cells into dendritic cell-like leukaemia cells 
(DLLCs), which then exhibit enhanced immunostimulatory capabilities (Kremser, et al 2010). 
These DLLCs can then be delivered into the patient to illicit an anti-leukaemia immune 
response. However, studies have suggested that these DLLCs retain some 
immunosuppressive characteristics, such as high PD-L1 expression, that continue to impair 
the desired T cell responses (Curti, et al 2010, Ge, et al 2009, Li, et al 2006). 
Rather than modifying AML cells to better present leukaemic antigens, monocyte-derived 
DCs can also be loaded with leukaemia-specific peptides and then delivered to patients as a 
DC vaccine. Loading of DCs from AML patients in remission with leukaemia-specific 
peptides, followed by administration, improved the period of relapse-free survival 15-fold in 
responders compared to non-responders (Lichtenegger, et al 2013). Other studies 
demonstrated that such DC vaccines were able to induce various T cell responses (Kitawaki, 
et al 2011a, Kitawaki, et al 2011b). DC vaccination may therefore prove most useful in 
preventing relapse in AML patients in remission and managing minimal residual disease. 
Genetically engineering T cells to recognize specific cell-surface antigens and kill the cells 
upon which the antigen is expressed has also been shown to be a very promising approach. 
The transfer of T cells expressing a particular chimeric antigen receptor (CAR), consisting of 
the CD3 transmembrane domain fused to the variable region of an anti-CD19 antibody, into 
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patients with various B cell malignancies has demonstrated potent therapeutic efficacy 
(Kochenderfer, et al 2012, Porter, et al 2011), and CARs directed against various other 
antigens are being investigated. Although no AML-specific CAR T cells are currently in 
clinical trials, early in vitro and in vivo studies have demonstrated that T cells with a CAR 
directed against CD33 are able to exert specific anti-leukaemia effects without major 
adverse reactions against normal haematopoietic cells (Dutour, et al 2012). 
1.6.6 Differentiation therapy of AML 
Although the success of ATRA/ATO in inducing terminal differentiation of APL is restricted 
only to the M3 subtype, it has illustrated the promise and value of differentiation therapy in 
AML. Differentiation of immature AML blasts into more mature cells may lead to alleviation of 
AML-associated symptoms and enhanced anti-leukaemia immune responses, without the 
excessive and non-specific cytotoxicity (Mughal, et al 2010) associated with chemotherapy. 
Because ATRA is only able to induce differentiation in APL cells that carry the t(15;17) 
translocation, differentiating agents that have efficacy in other AML subtypes are under 
investigation. 
Various combinations of cytokines, including GM-CSF, IL-4, IL-3, SCF and TNF-α, and many 
chemical agents, such as calcium ionophores and phorbol diesters, have been found to 
effectively and rapidly induce terminal differentiation of AML cells from almost all patients to 
dendritic cell-like leukaemia cells in vitro. However, these approaches are either not feasible 
or have thus far been ineffective in vivo and in clinical trials (Koeffler 2010, Westers, et al 
2003). Other potential agents include DNA methylation inhibitors and histone deacetylase 
(HDAC) inhibitors that aim to relieve the aberrant hypermethylation and repression of genes 
important for normal myelopoiesis. These drugs, however, tend to have low selectivity 
towards individual HDAC family members and cause a variety of undesirable, non-specific 
effects such as non-specific cytotoxicity and increased proliferation of leukaemic stem cells 
(Bug, et al 2007, Ferguson, et al 2011, Zelent, et al 2005). Some tyrosine kinase inhibitors, 
aimed primarily at inhibiting proliferation, are also able to induce moderate differentiation in 
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AML cell lines (Stegmaier, et al 2005) in vitro. Ultimately, no clinically effective differentiation 
therapy currently exists for the treatment of non-APL AML. 
 
1.7 CD137-CD137L interactions in AML 
The role of CD137-CD137L interactions in AML has been explored in a handful of studies. 
Surface expression of CD137L could be detected in 35% of AML patients tested in one study 
(Baessler, et al 2010). Although expression varies considerably between individual patients, 
higher surface CD137L expression is found in AML cells with monocytic differentiation (i.e. 
FAB subtypes M4 and M5), while lower expression is associated with the M0, M1 and M2 
subtypes (Baessler, et al 2010, Salih, et al 2004). Interestingly, patients with lower surface 
expression of CD137L have correspondingly higher levels of soluble CD137L (sCD137L), 
higher blast counts, poorer prognoses and lower long term survival rates. Patients with 
higher surface expression and lower levels of sCD137L demonstrate improved remission 
and long term survival rates (Hentschel, et al 2006, Salih, et al 2004). Taken together, this 
suggests that CD137L expressed on AML cells enhances tumour immunogenicity and that 
the surface protein may be shed as a means of immune evasion. 
Indeed, CD137L has been found to stimulate and promote anti-leukaemia T cell responses. 
In the presence of recombinant CD137L, dendritic cell-like leukaemia cells generated from 
AML cells were able to enhance the proliferation and differentiation of naïve T cells to 
CD45RA+, CD27- effector cells that secreted high levels of IFN-γ and exhibited increased 
leukaemia-specific cytolytic capacity, compared to T cells not treated with recombinant 
CD137L (Houtenbos, et al 2007). HDACi-induced up-regulation of CD137L expression on 
several AML cell lines lead to reduced apoptosis, enhanced proliferation and IFN-γ secretion 
by co-cultured T cells – an effect that was abolished upon addition of antagonistic anti-
CD137 antibodies (Vire, et al 2009). Administration of monoclonal anti-CD137 antibodies 
into mice challenged with AML cells was able to induce donor lymphocyte-mediated 
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elimination of the AML cells and substantially prolong the survival of these anti-CD137-
treated mice, indicating that CD137 activity also enhances graft-verus-leukaemia effects 
(Blazar, et al 2001). Shedding of CD137L from the AML cell surface leads to correspondingly 
diminished T cell activity and the binding of sCD137L may even block subsequent CD137-
signalling on T cells (Scholl, et al 2009). 
In contrast to the previous observations, CD137L expression on AML cells appears to have 
inhibitory effects in NK cells. Ligation of CD137 expressed on the NK cells lead to impaired 
granule mobilization, IFN-γ secretion, leukaemia-specific cytotoxicity and increased 
secretion of the anti-inflammatory IL-10 – effects that were abrogated by addition of blocking 
anti-CD137 antibodies (Baessler, et al 2010). This suggests that CD137L expression 
provides a selective advantage to the AML cells and facilitates immune evasion. Continued 
research in this area would further elucidate the roles and effects of CD137/CD137L 
signalling in AML and help to resolve any apparent inconsistencies.  
 
1.8 Research objectives 
Barring the M3 subtype, no clinically effective differentiation therapy for AML currently exists. 
Preliminary studies have illustrated the potential of both differentiation therapy and 
immunotherapy in the treatment of haematological malignancies. Studies have 
demonstrated that CD137L signalling can drive the differentiation of haematopoietic 
progenitor cells to macrophages (Jiang, et al 2008a, Jiang, et al 2008b), monocytes to DCs 
(Ju, et al 2009, Kwajah and Schwarz 2010), and induce maturation of immature DCs 
(Kwajah and Schwarz 2010, Lippert, et al 2008). It therefore follows that CD137L signalling 
may also be able to induce differentiation of AML cells, which are essentially immature 
myeloid cells that possess a characteristic block in differentiation. No studies have yet been 
undertaken to investigate this. Additionally, research on the roles of CD137/CD137L in AML 
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have primarily been concerned with the anti-leukaemic effects of CD137 signalling in T cells; 
very little is currently known about the effects of CD137L signalling into AML cells. 
Therefore, this thesis aims to: 
1. Investigate the effects of CD137L signalling in primary AML cells and to determine 
whether CD137L signalling can induce differentiation of AML. 
2. Explore possible methods of delivering CD137L signals in vivo. 










2.1 Recombinant proteins 
CD137-Fc protein was purified from the supernatants of stable transfected CHO cells by 
protein G sepharose, as described previously (Schwarz, et al 1996). Human IgG1 Fc protein 
was purchased from Chemicon International. Human recombinant GM-CSF and IFN-γ were 
purchased from Peprotech Inc.  
2.2 Cells and cell culture 
2.2.1 Patient samples 
AML patient samples were collected at the Singapore General Hospital and the National 
University Cancer Institute, Singapore under protocols approved by the institutional review 
boards. Peripheral blood or bone marrow samples were taken from patients with AML at 
time of diagnosis following written informed consent. Mononuclear cells were isolated by 
density gradient centrifugation using Ficoll-Paque (1.077g/dl, GE Life Sciences). Diagnosis 
was established by cytological criteria based on the FAB classification. Freshly isolated 
mononuclear cells were cultured immediately, or cryopreserved cells were cultured 
immediately after recovery, at a density of 2 x 106 cells/ml in polystyrene culture dishes 
(Becton Dickinson) coated with 10 µg/ml Fc or 10 µg/ml CD137-Fc protein, in RPMI-1640 
medium (Sigma-Aldrich) supplemented with 10% FBS, 50 µg/ml streptomycin and 50 IU/ml 
penicillin, at 37°C. 
2.2.2 Recovery of cryopreserved AML cells 
Vials containing 1 mL of cryopreserved AML cells were thawed from liquid nitrogen storage 
by swirling in a 37°C water bath for 2 minutes. The cells were then placed immediately into 
30 mL RPMI-1640 medium and centrifuged at 300g for 5 minutes, followed by one more 
wash. Cells were then stained with Trypan Blue and viable cells were counted using a 
haemocytometer.  
2.2.3 Cell lines 
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The stable CD137-transfected L428 cell line was kindly provided by a colleague, Ho Weng 
Tong. Briefly, the Hodgkin’s and Reed-Sternberg (HRS) cell line, L428, was obtained from 
the German Collection of Microorganisms and Cell Cultures (DSMZ) and was authenticated 
by DSMZ using DNA-typing, PCR analysis and cytogenetic testing. Stable cell lines 
expressing CD137 were generated by lentiviral transduction. Full-length cDNA of CD137 
was cloned into pLenti6 vector (Invitrogen). The cells were transduced with CD137 viral 
supernatant and subsequently selected with blasticidin (100 mg/mL).  
2.2.4 Murine AML cells 
A murine model of leukaemia, utilizing conditional Cbfb knock-out mice, was established and 
kindly provided to us by A/Prof. Motomi Osato. Briefly, Cbfbfl/fl mice were back-crossed to 
mice in the C57BL/6 background for at least 3 generations before being used for subsequent 
crosses. To generate conditional Cbfb knock-out mice, Cbfbfl/fl mice were crossed with Mx1-
Cre+ mice to obtain Cbfbfl/fl; Mx1-Cre+ and Cbfbfl/fl; Mx1-Cre- littermate controls on the 
C57BL/6 background. To excise the floxed allele, 4-week old Cbfbfl/fl; Mx1-Cre+ and Cbfbfl/fl; 
Mx1-Cre- mice were intra-peritoneally injected with 1400 mg of pIpC on 7 alternate days. 
Time points after pIpC induction were counted from the last day of injection. To avoid 
immediate suppressive effects on haematopoiesis by interferon induced by pIpC, the mice 
were subjected to experiments at least 4 weeks after pIpC injection. 
To harvest bone marrow cells, mice were first euthanized by CO2 inhalation. The femur 
bones were dissected and the bone marrow was flushed out aseptically with phosphate-
buffered saline (PBS) + 2 mM EDTA using a 10 ml syringe and 27G needle. Total bone 
marrow cells were passed through a 30 µm filter (Miltenyi Biotec) and washed with PBS + 2 
mM EDTA. Bone marrow cells were then cultured at a density of 2 x 106 cells/ml in 
polystyrene culture dishes coated with 10 µg/ml Fc or 10 µg/ml CD137-Fc protein, in RPMI-
1640 medium supplemented with 10% FBS, 50 µg/ml streptomycin and 50 IU/ml penicillin. 
2.3 Immunophenotypic analysis by flow cytometry 
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Flow cytometric analysis was to determine surface marker expression. Cells were stained 
with antibodies in PBS containing 0.5% BSA and 0.1% sodium azide (FACS buffer) at 4°C 
for 30 min. Non-specific staining was controlled by labelling with isotype-matched antibodies. 
Cells were then washed and resuspended in 300 µl FACS buffer. Flow cytometry was 
performed on a CyAn FACS machine (Dako). 
Antibodies directed against the following human antigens were used: CD117-PE (clone 
104D2), CD34-APC (clone 4H11), CD14-APC (clone 61D3), CD36-FITC (clone NL07), 
CD11b-PE (clone ICRF44), CD13-APC (clone WM15), CD80-PE (clone 2D10.4), CD86-PE 
(clone IT2.2), CD40-PE (clone FC3), CD83-APC (clone HB15E), HLA-DR-APC (clone LN3), 
CD45-PE-Cy7 (clone HI30) (all from eBioscience), CD137L-PE (clone 5F4) (Biolegend) and 
CD137-PE (BD Biosciences). Forward- and side-scatter characteristics in combination with 
CD45 expression were used to identify viable AML cells of interest. 
Antibodies directed against the following murine antigens were used: CD3-PE (clone 17A2), 
CD11b-PE (clone M1/70), Gr-1-PE (clone RB6-8C5), TER-119-PE (clone TER-119), B220-
PE (clone RA3-6B2), CD19-PE (clone 6D5), CD3-PE (clone 145-2C11), CD11c-PE (clone 
N418), F4/80-PE (clone BM8), c-Kit-FITC (clone 2B8), FLT3-PerCP 710 (clone A2F10), 
Sca1-APC (clone D7) and CD34-AlexaFluor 700 ( clone RAM34) (all from eBioscience). 
2.4 Functional assays 
2.4.1 Assessment of phagocytosis 
Cells were incubated with Yellow-Green fluorescent FluoroSphere microspheres (Invitrogen) 
at a concentration of 50 beads per cell at 37°C for 45 min. Phagocytosis was stopped by the 
addition of ice-cold PBS, cells were washed and treated with trypsin for 5 min to detach any 
surface-adherent beads. Cells were washed again and resuspended in 300 µl PBS. Flow 
cytometry was performed to determine percentage of cells that had phagocytosed beads. 
2.4.2 Transwell migration assay 
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The effect of CD137 on in vitro migration of AML cells was assayed by a method using 
Matrigel-coated Boyden chambers. Cells were harvested after Fc- or CD137-Fc-treatment, 
washed twice and starved for 4 hours at 4°C in serum-free RPMI-1640 media. 24-well 
Transwell cell culture chambers with 5.0 µm-pore polycarbonate inserts (Corning 
Incorporated) were coated with 100 µL Matrigel (BD Biosciences) for 2 hours at 37°C and 
then washed. 100 µL cell suspension was then placed into the Matrigel-coated chambers at 
a density of 6 x 105 cells/mL in serum-free RPMI-1640 media. These chambers were then 
placed into 24-well culture dishes containing 500 µL RPMI-1640 supplemented with 10% 
FBS as a chemoattractant and incubated for 24 hours at 37°C. After the incubation period, 
invasive cells that had migrated into the bottom chamber were stained with trypan blue and 
counted under a light microscope. 
2.4.3 Assessment of AML proliferation 
AML cells were stained with CFSE (Invitrogen) according to the manufacturer’s instructions 
prior to culture. Briefly, cells were resuspended in PBS containing 0.5% BSA, 2 mM EDTA 
and 10 mM CFSE, at a cell density of 2 million/mL, for 10 minutes. Cells were then washed 3 
times in a 10-fold greater volume of RPMI-1640. CFSE-stained cells were then cultured in 
tissue culture dishes. After 7 days of Fc- or CD137-Fc-treatment, proliferation was induced 
by addition of 50 ng/mL IFN-γ and 10 ng/mL GM-CSF (Peprotech) to the culture media. After 
an additional 4 days, the cells were harvested and CFSE dilution was assessed by flow 
cytometry. Alternatively, cells were pulsed with 0.5 µCi of 3H-thymidine (Perkin Elmer) for the 
last 18 hours of the culture period. The cells were then harvested onto a Packard Unifilter 
Plate using a MicroMate 196 Cell Harvester and analysed for incorporation of 3H-thymidine 
using TopCount Microplate Scintillation Counter (Perkin Elmer). Each condition was assayed 
in triplicate. 
2.5 Detection of cytokine secretion by ELISA 
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The concentrations of IL-8, TNF-α, MCP-1, M-CSF, IL-10, IL-12p70, IL-23, IFN-γ, IL-13 and 
IL-17 in culture supernatants were measured using the respective R&D DuoSet ELISA kits 
(R&D Systems) according to the manufacturer’s instructions. Samples were assayed in 
triplicate within each experiment. 
2.6 Allogeneic mixed lymphocyte reaction 
The ability of Fc or CD137-Fc-treated AML cells to stimulate T cells was assessed in an 
allogeneic mixed lymphocyte reaction (MLR). Peripheral blood mononuclear cells (PBMC) 
were isolated from buffy coat of healthy donors by density gradient centrifugation using 
Ficoll-Paque (1.077g/dl, GE Life Sciences), followed by positive-selection of CD3+ T cells 
using CD3 Microbeads (Miltenyi Biotec) according to the manufacturer’s instructions. Fc- 
and CD137-Fc-treated AML cells were harvested after 7 days of culture and subsequently 
co-cultured with CD3+ T cells at a ratio of 1:10 and density of 106 cells/ml. Co-cultures were 
sub-optimally activated with 1.1 ng/ml of agonistic anti-CD3 antibody (clone OKT-3) and 
maintained in RPMI-1640 supplemented with 10% FBS, 50 µg/ml streptomycin and 50 IU/ml 
penicillin for 5 days. To assess T cell proliferation, T cells were stained with CFSE 
(Invitrogen) according to the manufacturer’s instructions prior to co-culture. CFSE dilution 
was assessed by flow cytometry. Supernatants were collected for detection of cytokine 
secretion by ELISA. 
2.7 Cell morphology 
Morphology of Fc- and CD137-Fc-treated cells was evaluated after 7 days of culture. Cell 
smears were obtained by air-drying of cell suspensions onto a glass slide followed by 
staining with a modified wright-giemsa stain. Bright-field light microscopy photographs were 
taken using the Zeiss Axiovert 40 inverted microscope (Zeiss) and Canon Powershot G6 
digital camera. 
2.8 Transfer of CD137 from donor to recipient cells 
 33 
 
Transfer of CD137 from CD137-expressing cells to CD137L-expressing cells was examined 
by co-culture of donor and recipient cells. PBMCs were isolated as previously described, 
followed by positive selection of monocytes using Monocyte Isolation Kit II (Miltenyi Bioitec) 
according to the manufacturer’s instructions. CD137-transfected L428 cells, or empty vector-
transfected cells, were co-cultured with monocytes at a ratio of 1:5 and a cell density of 1 x 
106 cells/ml for 2 hours.  
Alternatively, CD3+ T cells were isolated as previously described and activated with 5 µg/mL 
of agonistic anti-CD3 antibody (clone OKT-3) for 48 hours to induce CD137 expression. 
Activated or resting T cells were then co-cultured with monocytes or AML cells at a ratio of 
2:1 and density of 1 x 106 cells/ml for 2 hours. 
Cells were then harvested, stained with the appropriate fluorochrome-conjugated antibodies 
and assessed for evidence of CD137-transfer by flow cytometry. 
2.9 Allogeneic MLR with monocytes possessing transferred CD137 
After 2 hours of co-culture with CD137-expressing cells, monocytes were isolated from the 
initial co-culture and subsequently co-cultured with allogeneic CD3+ T cells in a mixed 
lymphocyte reaction, as described previously. After 3 days, supernatants were collected for 
the detection of cytokine secretion by ELISA. 
2.10 CD137/CD137L localization by confocal microscopy 
AML cells were fixed with 4% PFA for 15 minutes at 37°C and permeabilized with 1% Triton-
X 100. The cells were blocked with 1% BSA for 1 hour at room temperature, followed by 
staining with anti-CD137 antibody (clone BBK-2) overnight at 4°C. The cells were then 
stained with APC-conjugated donkey anti-mouse antibody for 1 hour at room temperature, 
washed, then stained with PE-conjugated anti-CD137L antibody (clone 5F4) for 1 hour at 
room temperature. Non-specific staining was controlled by labelling with isotype-matched 
antibodies. Cells were then mounted on polylysine slides. The slides were visualized with 
Olympus Fluoview FV1000 TIRF. 
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2.11 Immobilization of CD137-Fc on red blood cell membrane 
Recombinant CD137 protein was immobilized onto the cell surface membrane of red blood 
cells by separately biotinylating CD137-Fc protein and the red blood cell surface memrane, 
then conjugating one to the other via an avidin ‘bridge’. This protocol was adapted from 
(Sternberg, et al 2012). 
CD137-Fc was biotinylated with Sulpho-NHS-biotin (Thermo Scientific) according to the 
manufacturer’s instructions. Unbound biotin was removed by passing through Zeba Spin 
Desalting Column (Thermo Scientific). Separately, red blood cells (RBCs) were separated 
from buffy coat by centrifugation (1000g, 10 minutes) and washed twice with PBS. 100 µL of 
packed RBCs was resuspended in 400 µL PBS and incubated with 10 µg (1 mg/mL) Sulpho-
NHS-biotin (Thermo Scientific) for 1 hour at room temperature. Cells were then centrifuged 
(500g, 5 minutes) and washed twice with PBS. RBCs were then resuspended in 1 mL of 100 
µg/mL avidin and incubated for 1 hour at room temperature. Cells were then centrifuged 
(500g, 5 minutes) and washed twice. Finally, the biotin-avidin-RBCs were resuspended in 
200 µL PBS, to which 50 µL of biotinylated CD137-Fc (100 µg) was added, and incubated 
for 1 hour at room temperature. RBCs were washed twice with PBS and resuspended in 
2000 µL RPMI-1640 medium supplemented with 10% FBS, 50 µg/ml streptomycin and 50 
IU/ml penicillin. RBCs were stored at 4°C until use. 
2.12 Statistics 
Where relevant, statistical significance was determined by a two-tailed unpaired Student’s t-










3.1 Effects of CD137L signalling in cryopreserved acute myeloid leukaemia cells 
Previous studies done in our laboratory demonstrated that CD137L signalling induces 
differentiation of murine and human haematopoietic progenitor cells into macrophages 
(Jiang, et al 2008a). Human peripheral blood monocytes also differentiate into dendritic cells 
(DCs) in response to CD137L signalling (Kwajah and Schwarz 2010). Since acute myeloid 
leukaemia (AML) cells are essentially myeloid cells with differentiation arrested at various 
stages of development, we wanted to see if CD137L signalling could induce a similar effect 
on them, thereby removing the maturation block characteristic of AML and promoting 
terminal differentiation. 
The simplest and most practical approach, initially, was to work with cells derived from bone 
marrow aspirates biopsied from AML patients at the time of diagnosis, cryopreserved and 
stored in a tissue repository. These samples were kindly provided by Dr Linn Yeh Ching from 
Singapore General Hospital. 
3.1.1 CD137L signalling induces little to no change in the immunophenotype of AML 
cells 
Myeloid cells at various stages of development express distinct levels of immature, mature 
and cell-specific surface markers that, taken together, provide a useful frame of reference for 
determining the maturity of a particular population of cells. The differentiation of AML cells 
can therefore be monitored by changes in immunophenotype. Changes in the expression 
levels of a small panel of surface markers were measured in this study to provide evidence 
for CD137-induced differentiation.  
To examine the effects of CD137L signalling in AML cells, mononuclear cells were isolated 
from cryopreserved bone marrow aspirates taken from AML patient samples. These cells 
were placed into culture dishes coated with a recombinant protein consisting of the 
extracellular domain of CD137 fused to the Fc region of human IgG (CD137-Fc). Cells 
cultured in dishes coated only with the Fc protein were used as negative controls. After 7 
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days, the cells were harvested and analysed. To distinguish the relevant myeloid population 
from the other mononuclear cells, a gating strategy based on expression of the pan-
leukocyte marker, CD45, and forward-scatter and side-scatter characteristics was used. 
Only these myeloid cells were selected for analysis (Figure 1). In a representative sample, 
minor immunophenotypic changes were observed between the CD137-treated cells and the 
negative control (Figure 2). Expression of CD34, a haematopoietic progenitor cell marker 
that is down-regulated upon maturation of myeloid progenitor cells, was substantially 
decreased by treatment with recombinant CD137. The monocyte marker, CD14, was down-
regulated slightly, while the co-stimulatory molecules CD80 and CD86, which are expressed 
at higher levels on DCs, were up-regulated slightly. Although the changes observed in this 
representative sample were comparatively more pronounced than those in the remaining 
samples (data not shown), these changes were minor and did not provide convincing 
evidence that the AML cells had undergone a considerable degree of differentiation. 
3.1.2 CD137L signalling induces cytokine secretion from a proportion of AML cells 
Culture supernatants were also harvested after 7 days and tested for the presence of the 
pro-inflammatory cytokines IL-8, TNF-α, MCP-1 and M-CSF, and the anti-inflammatory 
cytokine IL-10. Cytokine levels were increased 2 – 20-fold in a proportion of CD137-treated 
cells compared to the control cells (Figure 3). 
A total of 15 cryopreserved AML samples were analysed in this manner (Table 1). 
Expression of CD137L could be detected in 10 samples. Only 7 demonstrated a significant 
induction of cytokine secretion in response to treatment with recombinant CD137. None of 
the samples displayed enhanced secretion of more than 3 cytokines, while 3 samples 
showed enhanced secretion of only 1 cytokine. None of the samples demonstrated 
particularly marked changes in immunophenotype. Furthermore, many of the samples did 
not remain viable over long culture periods, with most of the cells having died by day 4 





Figure 1. Gating strategy used to identify myeloid population. Mononuclear cells isolated 
from bone marrow samples were stained with CD45 and analysed by flow cytometry. A 
plot of pulse width vs. forward-scatter was used to exclude doublet cells (1). This gate 
was applied to a plot of forward-scatter vs. side-scatter, which was used to exclude the 
majority of dead cells and cell debris (2). Finally, this gate was applied to a plot of CD45 
vs. side-scatter (3), where the black circle indicates the relevant myeloid population to be 




Figure 2. CD137 induces only minor changes in immunophenotype of frozen AML 
samples. AML cells were cultured for 7 days in dishes coated with immobilized Fc or 
CD137-Fc protein. Cells were then harvested and expression of a panel of surface 
markers was determined by immunostaining followed by flow cytometry. Depicted are 
histograms from one representative sample, Sample A11. The open profile shows the 
isotype control while the shaded profiles show expression of the relevant surface marker. 
Numbers indicate the percentage of cells expressing the surface marker and the median 




Figure 3. CD137 induces secretion of cytokines from several frozen AML samples. AML 
cells were cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. 
Supernatants were then harvested and concentrations of cytokines were determined by 






Table 1. Frozen AML samples tested. Samples are listed according to FAB classification. 
The percentage of CD137L-expressing cells was determined by flow cytometry 


















Figure 4. Majority of AML cells from frozen samples die within 7 days of culture. AML 
cells were cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. 
Cells were then harvested and analysed by flow cytometry. Depicted is a plot of side-
scatter vs. forward-scatter from one representative sample, Sample A12. Black circle 




 cryopreserved AML cells and may be functional, these cells remain largely resistant to 
CD137-induced differentiation. 
 
3.2 Effects of CD137L signalling in freshly isolated AML cells 
Although cryopreserved AML samples were resistant to differentiation, there was evidence 
that the CD137L expressed on the AML cells was functional. It was also possible that the 
process of cryopreservation reduced the sensitivity of the AML cells to differentiation. It was 
thus worthwhile to explore effects of CD137L signalling in freshly isolated AML cells. 
Mononuclear cells from bone marrow or peripheral blood obtained from AML patients at the 
time of diagnosis were analysed or cultured immediately, without cryopreservation. These 
samples were kindly provided by Dr Chng Wee Joo from National University Hospital and Dr 
Linn Yeh Ching from Singapore General Hospital. 
3.2.1 CD137L signalling induces immunophenotypic changes in AML cells 
consistent with differentiation 
Mononuclear cells from freshly obtained AML samples were placed immediately into culture 
dishes coated with CD137-Fc or Fc protein. After 7 days, the cells were harvested and 
analysed. AML cells treated with CD137-Fc acquired a more mature immunophenotype 
compared to control cells. In a representative sample (Figure 5A), both the median 
fluorescence intensity (MFI) and percentage of cells expressing CD117, a hematopoietic 
progenitor cell marker that is down-regulated upon maturation of myeloid progenitor cells, 
were strongly decreased. This was accompanied by pronounced up-regulation of the 
myelomonocytic markers CD11b and CD13, which are highly expressed on mature myeloid 
cells. The cells also acquired the co-stimulatory molecules CD80, CD86 and CD40, which 
are expressed on DCs. A representative AML sample with a monocytic immunophenotype 




Figure 5. CD137 induces immunophenotypic changes in AML cells consistent with 
differentiation. AML cells were cultured for 7 days in dishes coated with immobilized Fc or 
CD137-Fc protein. Cells were then harvested and expression of a panel of surface 
markers was determined by immunostaining followed by flow cytometry. Depicted are 
histograms from two representative samples. The open profile shows isotype control 
while the shaded profiles show expression of the relevant surface markers. Numbers 
indicate the percentage of cells expressing the surface marker and the MFI. (A) Sample 





Figure 5 (continued). CD137 induces immunophenotypic changes in AML cells 
consistent with differentiation. (B) Sample B20, monocytic cells of unknown subtype. This 
data is representative of at least 3 independent experiments with comparable results. 
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molecule, HLA-DR, together with increased expression of CD13, CD40 and the DC marker, 
CD83. Fc-treatment had minimal or no effect on the immunophenotype when compared to 
untreated cells analysed at the beginning of the study (data not shown). 
3.2.2 CD137L signalling induces cytokine secretion by AML cells 
Treatment of AML cells with recombinant CD137 strongly induced secretion of the pro-
inflammatory cytokines IL-8, TNF-α and MCP-1, and the anti-inflammatory cytokine IL-10 by 
5 – 20-fold, compared to control cells (Figure 6). IL-12 and IL-23, which are secreted by 
DCs and play roles in T cell activation and polarization, could not be detected in any of the 
AML culture supernatants (data not shown). 
3.2.3 CD137L signalling induces morphological changes in AML cells that are 
consistent with DC differentiation 
Several samples also acquired morphologies characteristic of dendritic cells in response to 
treatment with recombinant CD137 (Figure 7). The majority of these cells became adherent 
and adopted flattened, spindle-shaped morphologies with extension of pseudopodia. Control 
cells remained round, often appeared smaller and did not adhere as strongly to the culture 
dishes. 
3.2.4 CD137L signalling increases CD83 expression and reduces phagocytosis in 
monocytic AML cells 
CD137L signalling induces differentiation of human peripheral monocytes to DCs (Kwajah 
and Schwarz 2010). Since this differentiation is accompanied by up-regulation of the DC-
specific marker, CD83, and decrease in phagocytic ability, we investigated whether AML 
cells would also acquire similar DC-like characteristics upon treatment with recombinant 
CD137. When monocytic AML cells (mainly of the M5b subtype and characterized by high 
CD14 expression) were treated with CD137-Fc, the percentage of cells expressing CD83 
was markedly increased (Figure 8A). Additionally, both the percentage of phagocytic cells 




Figure 6. CD137 induces secretion of cytokines by AML cells. AML cells were cultured 
for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. Supernatants were 
then harvested and concentrations of several cytokines were determined by ELISA. 
Depicted are means ± standard deviations of triplicate measurements from one 
representative sample, Sample B19. (*P < 0.05). This data is representative of at least 3 





Figure 7. CD137 induces adherence and morphological changes in AML cells. AML cells 
were cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. 
Photographs showing cell morphologies were taken on Day 7 by bright-field light 
microscopy at a magnification of 400X. Depicted are morphologies from 3 different AML 






Figure 8. CD137 induces up-regulation of CD83 and decreases phagocytosis in 
monocytic AML cells. AML cells were cultured for 7 days in dishes coated with 
immobilized Fc or CD137-Fc protein. Cells were then harvested and analysed. (A) CD83 
expression was determined by immunostaining followed by flow cytometry. Depicted are 
histograms from three AML samples. The open profile shows isotype control while the 
shaded profile shows expression CD83. Number indicates percentage of cells expressing 
CD83. (B) Phagocytosis was determined by incubation and uptake of fluorescent latex 
beads 45 minutes before analysis by flow cytometry. Depicted are histograms from two 
AML samples. The open profile shows cell auto-fluorescence while the shaded profile 
shows phagocytic cells. Numbers indicate percentage of phagocytic cells and MFI. This 
data is representative of at least 3 independent experiments with comparable results. 
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(Figure 8B). These changes, which were observed only in AML cells of monocytic origin, 
were consistent with differentiation into DC-like cells. 
3.2.5 AML cells treated with CD137 exhibit enhanced migratory ability 
CD137-treatment enhances migration of monocytes in vitro (Drenkard, et al 2007) and up-
regulates expression CCR7, a chemokine receptor that facilitates migration of DCs to lymph 
nodes (Kwajah and Schwarz 2010). Consistent with these observations, CD137-treated AML 
cells also possess enhanced migratory potential. After 7 days of treatment with CD137-Fc or 
Fc protein, the cells were harvested and placed into Boyden chambers. After 24 hours, a 2-
fold greater number of CD137-treated AML cells were able to migrate across the Matrigel-
coated porous membrane towards a chemoattractant, compared to control cells (Figure 9). 
3.2.6 AML cells treated with CD137 exhibit enhanced T cell co-stimulatory activity 
In addition to the mounting evidence that these AML cells were undergoing CD137-induced 
differentiation and maturation, it was necessary to determine whether CD137-treated AML 
cells were able to more effectively co-stimulate T cells. After 7 days of treatment with either 
CD137-Fc or Fc protein, the AML cells were harvested and co-cultured with CFSE-labelled 
allogeneic T cells in a mixed lymphocyte reaction. T cells stimulated with CD137-treated 
AML cells demonstrated higher proliferation compared to those stimulated with Fc-treated 
AML cells, as indicated by large differences in the percentage of proliferating T cells and 10-
fold decrease in MFI (Figure 10A). Furthermore, T cells co-cultured with CD137-treated 
AML cells released 3 – 6-fold higher levels of the pro-inflammatory cytokines IFN-γ, IL-13 
and IL-17 compared to control cells (Figure 10B). These results demonstrate that CD137-
treated AML cells possess enhanced T cell-activating capacity. 
3.2.7 AML cells treated with CD137 possess reduced proliferative capacity 
To determine whether the observed differentiation of the AML cells resulted in decreased 




Figure 9. CD137-treated AML cells demonstrate increased invasiveness. AML cells were 
cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. Cells were 
then harvested and 100 µL cell suspension containing 6 x 104 cells was placed into 
Matrigel-coated Transwell chambers suspended over a lower chamber containing 10% 
FBS as a chemoattractant. After 24 hours, cells that had migrated across the Transwell 
membrane into the lower chamber were counted. Depicted are means ± standard 
deviations of triplicate measurements from one representative sample, Sample B21. (*P < 





Figure 10. CD137-treated AML cells enhance allogeneic T cell activation. AML cells were 
cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc protein. They were 
then harvested and co-cultured with CFSE-labelled allogeneic T cells at a ratio of 1:10. 
The co-cultures were sub-optimally activated with agonistic anti-CD3 antibody (clone 
OKT-3). After 5 days, T cells were harvested and analysed. Depicted are results from a 
representative sample, Sample B18. (A) T cell proliferation was determined by CFSE 
dilution and flow cytometry. Areas marked by horizontal bars indicate proliferative cells. 
Numbers indicate percentage of proliferating T cells and MFI of total cell population. (B) 
Concentration of several cytokines in co-culture supernatants was determined by ELISA. 
Depicted are means ± standard deviations of triplicate measurements. (*P < 0.05). This 
data is representative of 3 independent experiments with comparable results. 
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revealed that the AML cells were simply unable to proliferate in vitro in the absence of 
growth factors, proliferation was induced by the addition of IFN-γ and GM-CSF into the 
culture medium on Day 7 of treatment with CD137-Fc or Fc protein. After 4 additional days, 
CD137-treated AML cells demonstrated a significantly reduced proliferation rate compared 
to the control cells, as indicated by a lower percentage of proliferating cells, higher MFI of 
CFSE-labelled cells (Figure 11A) and lower incorporation of 3H-thymidine (Figure 11B). 
This data shows that CD137-induced differentiation of AML cells is accompanied by 
concomitant reduction in proliferative capacity. 
3.2.8 Patterns of observed changes induced by CD137L signalling depend on cell 
type from which AML is derived 
Since AML samples derived from a range of FAB subtypes with different stages of maturity 
were assessed for evidence of CD137-induced differentiation, the changes observed varied 
considerably between individual samples. The samples were therefore grouped into three 
categories, based on the initial stage of maturation and the myeloid cell-type from which the 
AML originated. AML blasts with minimal or no maturation were characterized by side-
scatter and moderate expression of the pan-leukocyte marker, CD45 (Figure 12A). These 
cells typically expressed high levels of the progenitor cell markers, CD117 and CD34, did not 
express CD11b or CD14 and were of the M1 or M2 subtype. Cells with a greater degree of 
maturation exhibited moderate side-scatter and CD45 expression (Figure 12B), co-
expressed CD117 or CD34 with CD11b and were of the M2, M4 or M5a subtype. Monocytic 
leukaemia cells had moderate to high side-scatter and high CD45 expression (Figure 12C), 
high CD14 expression and were of the M5b subtype. 
Upon treatment with recombinant CD137 protein, AML cells with minimal or no maturation 
(Table 2) down-regulated CD117 or CD34 while acquiring expression of CD11b in every 
sample tested. CD13 and HLA-DR were variably up-regulated in several samples. The 
secretion of pro-inflammatory cytokines was markedly increased by 2 – 100-fold in all 




Figure 11. CD137-treated AML cells demonstrate reduced proliferation. CFSE-labelled 
AML cells were cultured for 7 days in dishes coated with immobilized Fc or CD137-Fc 
protein, after which 50 ng/mL IFN-γ and 10 ng/mL GM-CSF was added to induce 
proliferation. After 4 days, cells were harvested and proliferation was quantified. Depicted 
are results from one representative sample, Sample B22. (A) CFSE dilution. Areas 
marked by horizontal bars indicate proliferative cells. Numbers indicate percentage of 
proliferating cells and MFI of total cell population. (B) 
3
H-thymidine incorporation. 
Depicted are means ± standard deviations of triplicate measurements. (*P < 0.05). This 





Figure 12. Side scatter characteristics and CD45 expression of bone marrow 
mononuclear cells from representative samples of different FAB subtypes. Depicted are 
plots of CD45 expression vs. side-scatter. Black circles indicate the population of AML 
blasts. (A) Sample B2, M1. (B) Sample B8, M2. (C) Sample B17, M5b.  
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down-regulated CD117 and CD34. Expression of CD11b and the monocyte marker, CD14, 
were profoundly enhanced in most of the samples, along with acquisition of the co-
stimulatory molecules CD86 and CD40. In CD14-positive monocytic AML cells (Table 4), 
changes in expression of CD117 and CD34 were less pronounced, as progenitor cell 
markers are no longer expressed on cells of monocytic origin. Expression of CD14 was 
decreased in 3 of 4 samples, HLA-DR was decreased in 2 samples and up-regulation of 
CD83 was observed with concomitant suppression of the phagocytic ability of these 
monocytic AML cells (as previously described in Figure 8). This combination of changes is 
similarly observed during CD137-induced differentiation of healthy monocytes to DCs 
(Kwajah and Schwarz 2010). With the exception of Samples B8, B15 and B17, treatment 
with CD137 protein enhanced secretion of at least two cytokines in every tested sample. 
Taken together, these results show that AML cells, upon induction of CD137L signalling by 
recombinant CD137 protein, exhibit different but recognizable patterns of immunophenotypic 
and functional changes depending on the stage of maturation or type of cell from which the 
leukaemic cell was derived, and these changes are consistent with progressing myeloid 
differentiation.  
22 freshly isolated AML samples of various subtypes were tested in this study (Table 5). Of 
these, 16 (73%) demonstrated evidence of having undergone some degree of differentiation 
in response to treatment with recombinant CD137 protein. In 6 samples, no changes in 
immunophenotype, cytokine release, morphology or cell functions were observed (data not 
shown). These samples were deemed unresponsive and resistant to CD137-induced 
differentiation. There did not appear to be a correlation between sensitivity to differentiation 
and cytogenetic characteristics or FAB subtype, as samples from each subtype were able to 
differentiate. Expression levels of CD137L did not associate with particular FAB subtypes 
and were highly variable even between responsive samples. CD137L expression did not 






Table 2. Fold change in MFI of surface markers and cytokine concentrations for CD137-
Fc-treated compared to Fc-treated AML cells with minimal or no maturation. Numbers in 
red indicate a greater than 1.8-fold change or marked increase in percentage of cells 
expressing the antigen. Means ± standard deviations of triplicate measurements from 
each sample were used to calculate fold change in cytokine concentrations. All values are 





Table 3. Fold change in MFI of surface markers and cytokine concentrations for CD137-
Fc-treated- as compared to Fc-treated AML cells with increased maturation. Numbers in 
red indicate a greater than 1.8-fold change or marked increase in the percentage of cells 
expressing the surface marker. Means ± standard deviations of triplicate measurements 
from each sample were used to calculate fold change in cytokine concentrations. All 





Table 4. Fold change in MFI of surface markers and cytokine concentrations for CD137-
Fc-treated- as compared to Fc-treated monocytic AML cells. Numbers in red indicate a 
greater than 1.8-fold change or marked increase in the percentage of cells expressing the 
surface marker. Means ± standard deviations of triplicate measurements from each 
sample were used to calculate fold change in cytokine concentrations. All values are 




Table 5. Freshly obtained AML samples tested. Samples are listed according to the FAB 
classification. The percentage of CD137L-expressing cells was determined by flow 
cytometry immediately after isolation of the cells. Samples in red indicate AML cells that 
were resistant to CD137-induced differentiation. (n.a.: not available). 
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3.3 Transfer of CD137 to AML cells 
A study by Ho et al found that CD137 could be transferred onto the surface of CD137L-
expressing Hodgkin and Reed-Sternberg (HRS) cells, thereby blocking further CD137-
CD137L interactions and inhibiting T cell co-stimulation (Ho, et al 2013, Pang, et al 2013). 
We therefore examined the possibility that a similar mechanism takes place with AML cells 
and explored the nature of this interaction.  
3.3.1 CD137 is transferred from cell lines to monocytes and inhibits subsequent 
cytokine release from T cells. 
CD137 can be transferred from CD137-expressing cell lines to HRS cells and healthy B cells 
(from which HRS cells are derived) (Ho, et al 2013). We examined whether CD137 could 
also be transferred to healthy myeloid cells. A stable transfected HRS cell line, L428, that 
overexpressed high levels of CD137 (Figure 13A), was co-cultured with monocytes to allow 
transfer of CD137 from the donor to recipient cells. After just 2 hours, monocytes that were 
co-cultured with CD137-expressing L428 cells became CD137-positive, while no CD137 
could be detected on monocytes co-cultured with the control empty vector-transfected cells 
(Figure 13B). Furthermore, when these CD137-positive monocytes were subsequently 
harvested and co-cultured with allogeneic T cells in a mixed lymphocyte reaction, IFN-γ 
secretion was reduced 2-fold, compared to T cells co-cultured with control monocytes 
(Figure 13C). 
3.3.2 CD137 is transferred from activated T cells to monocytes 
A likely source of donor CD137 during normal physiological conditions or disease states 
would be activated T cells; resting T cells do not express CD137. Activated T cells that 
expressed CD137, or resting T cells that did not (Figure 14A), were co-cultured with 
monocytes for 2 hours. CD137 was then detected on monocytes co-cultured with activated T 






Figure 13. CD137 is transferred from CD137-expressing L428 cells to monocytes and 
suppresses IFN-γ release by allogeneic T cells. CD137-transfected L428 cells, or empty 
vector-transfected cells, were co-cultured with monocytes at a ratio of 1:5 for 2 hours. 
Cells were then harvested and expression of CD137 was determined by immunostaining 
followed by flow cytometry. Depicted are histograms showing CD137 expression. Open 
histograms show the isotype controls while the shaded histograms show CD137 
expression. Numbers indicate percentages of cells expressing CD137 and MFI. (A) 
Expression of CD137 on empty vector-transfected and transfected L428 cell lines was 
determined prior to co-culture. (B) Presence of transferred CD137 on monocytes was 
determined after 2 hours of co-culture. (C) Monocytes with or without transferred CD137 
were isolated and co-cultured with allogeneic T cells at a ratio of 1:10 for 3 days. Co-
cultures were sub-optimally activated with agonistic anti-CD3 antibody (clone OKT-3). 
The concentration of IFN-γ in co-culture supernatants was then determined by ELISA. 
Depicted are means ± standard deviations of triplicate measurements. (*P < 0.05). This 




Figure 14. CD137 is transferred from activated T cells to monocytes. Autologous T cells 
were isolated and activated with immobilized anti-CD3 antibody (clone OKT-3) for 48 
hours. Activated or resting T cells were then co-cultured with monocytes at a ratio of 2:1 
for 2 hours. Cells were then harvested and expression of CD137 was determined by 
immunostaining followed by flow cytometry. Depicted are histograms showing CD137 
expression. Open histograms show the isotype controls while the shaded histograms 
show CD137 expression. Numbers indicate percentages of cells expressing CD137 and 
MFI. (A) Expression of CD137 on resting or activated T cells was determined prior to co-
culture. (B) Presence of transferred CD137 on monocytes was determined after 2 hours 




3.3.3 CD137 from activated T cells and immobilized recombinant CD137 is 
transferred to AML cells 
When freshly isolated AML cells were co-cultured with activated T cells, transferred CD137 
could be detected on the AML cells after just 2 hours (Figure 15A). The AML cells did not 
endogenously express CD137, nor was any CD137 detected on AML cells co-cultured with 
resting T cells. Recombinant CD137 protein immobilized on the surface of the culture dish 
was also readily transferred to the AML cells (Figure 15B). In several AML samples, very 
little or no CD137L could be detected by flow cytometry when anti-CD137L antibodies were 
used, but surface expression of CD137L was confirmed by this observed transfer and 
detection of recombinant CD137. 
3.3.4 The CD137-CD137L complex is internalized into AML cells that are sensitive to 
CD137-induced differentiation 
AML cells possessing transferred CD137-Fc from CD137-Fc-coated culture dishes were 
stained with appropriate antibodies and visualized by confocal microscopy in order to 
determine the localization of CD137L and transferred CD137-Fc protein. In 2 AML samples 
that had exhibited immunophenotypic evidence of differentiation, CD137L and CD137-Fc 
protein appeared to be co-localized within the cytoplasm of the cells after 2 hours of culture 
(Figure 16, Samples C1 and C2), as indicated by yellow-orange fluorescence in the merged 
images. Interestingly, both CD137L and CD137-Fc remained localized on the surface 
membrane of 2 additional AML samples that did not undergo differentiation in response to 
treatment with recombinant CD137 (Figure 16, Samples C3 and C4), suggesting that 
internalization of the CD137L-CD137 complex is required for initiation of signal transduction 






Figure 15. CD137 is transferred to AML cells from activated T cells and from the surface 
of a culture dish. Depicted are histograms from 2 separate AML samples showing CD137 
expression. Open histograms show the isotype controls while the shaded histograms 
show CD137 expression. Numbers indicate percentages of cells expressing CD137 and 
MFI. (A) Activated or resting T cells were co-cultured with AML cells at a ratio of 2:1 for 2 
hours. Cells were then harvested and the level of transferred CD137 was determined by 
immunostaining and flow cytometry. (B) AML cells were cultured for 2 hours in uncoated 
dishes or dishes coated with immobilized CD137-Fc. Cells were then harvested and the 
level of transferred CD137 was determined by immunostaining and flow cytometry. This 





Figure 16. The CD137L-CD137 complex is internalized into AML cells that are sensitive 
to CD137-induced differentiation, but remains on the surface membrane of AML cells that 
are resistant to differentiation. AML cells were cultured for 2 hours in culture dishes 
coated with immobilized CD137-Fc. Cells were then harvested, stained and localization of 
CD137L and CD137 was visualized by confocal microscopy. Depicted are photographs 
from 2 differentiation-sensitive samples (Samples C1 and C2) and 2 differentiation-
resistant samples (C3 and C4). Red fluorescence indicates CD137L expression, while 
green fluorescence indicates CD137 expression. Yellow-orange fluorescence in merged 
fields indicate co-localization of the two proteins. This data is representative of 5 
independent experiments with comparable results. 
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3.4 CD137L signalling induces differentiation of myeloid cells in a murine model of 
leukaemia 
After determining that recombinant CD137 was able to induce differentiation of human 
primary AML cells in vitro, it became important to reproduce these results in an in vivo 
setting. Previous studies have already demonstrated that murine CD137L signalling 
enhances myelopoiesis during infection (Tang, et al 2013) and induces differentiation of 
haematopoietic progenitor cells to macrophages (Jiang, et al 2008a), but we wanted to 
confirm that CD137L signalling also drives differentiation of transformed myeloid cells in a 
murine model of leukaemia.  
A murine model of leukaemia, utilizing conditional Cbfb knock-out mice, was established and 
kindly provided by A/Prof. Motomi Osato. In this model, Cbfbfl/fl;Mx1-Cre+ mice were injected 
with pIpC to induce expression of Cre recombinase, leading to excision of the floxed Cbfb 
alleles. Loss of Cbfb in these mice led to a differentiation block in the myeloid lineage and an 
expansion of the haematopoietic stem cell compartment. No differentiation blockages were 
observed in Cbfbfl/fl;Mx1-Cre- control mice. This model provided a useful tool for examining 
the effects of CD137L signalling on AML in vivo. 
The primary task was to determine whether the haematopoietic stem cells and myeloid cells 
from this AML model were sensitive to CD137-induced differentiation. Cbfbfl/fl;Mx1-Cre+ mice 
or Cbfbfl/fl;Mx1-Cre- control mice were sacrificed and bone marrow cells were extracted and 
cultured in dishes coated with recombinant CD137 protein or Fc protein for 5 days. Cells 
were then harvested and analysed for immunophenotypic changes indicative of 
differentiation.  
Within this short period, the percentage of Lineage-, c-Kit+ haematopoietic stem cells had 
dwindled from approximately 40.4% to 6.8% (Figure 17), indicating that these cells had 
spontaneously differentiated in both the Fc and CD137-Fc treatment groups. Because of 




Figure 17. Haematopoietic stem cells from Cbfb knockout mice spontaneously 
differentiate in vitro. Bone marrow cells from Cbfb knock-out mice were cultured 
for 5 days in dishes coated with immobilized Fc or CD137-Fc protein. Cells were 
then harvested and expression of surface markers was determined by 
immunostaining followed by flow cytometry. Depicted are scatter-plots showing 










 cells. This data is representative of 3 independent experiments with 
comparable results.  
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not be determined. In the remaining myeloid cells, however, treatment with recombinant 
CD137 resulted in increased expression of the monocyte marker, CD14, and the 
macrophage marker, F4/80. CD11b, which is expressed on both monocytes and 
macrophages, was up-regulated slightly. CD86 and CD11c, both of which are expressed at 
higher levels on DCs, were also slightly up-regulated. Interestingly, expression of the 
granulocyte marker, GR-1, was reduced in response to treatment with recombinant CD137 
(Figure 18). Taken together, these immunophenotypic changes suggest that CD137-
treatment is able to relieve the differentiation block of the myeloid lineage in Cbfb knock-out 
mice, allowing a proportion of myeloid cells to mature into monocytes, macrophages and 
DCs.  
In one instance, treatment with recombinant CD137 resulted in massive cell death of cells 
from the Cbfb knock-out mouse, but did not exert this effect on cells from the wild-type 
mouse (Figure 19). Although the reason for this is unclear, it is possible that the Cbfb 
knockout cells were particularly susceptible to over-activation by CD137-Fc and underwent 









































Figure 18. CD137 induces immunophenotypic changes consistent with myeloid 
differentiation in a mouse model of AML. Bone marrow cells from Cbfb knockout mice 
were cultured for 5 days in dishes coated with immobilized Fc or CD137-Fc protein. Cells 
were then harvested and expression of surface markers was determined by 
immunostaining followed by flow cytometry. Depicted are histograms showing surface 
marker expression. The open profile shows the isotype control while the shaded profiles 
show expression of the relevant surface marker. Numbers indicate the percentage of cells 
expressing the surface marker and the MFI. This data is representative of 3 independent 





Figure 19. CD137 induces apoptosis of bone marrow myeloid cells from a Cbfb knock-
out mouse, but not from the wild-type. Bone marrow cells from Cbfb wild-type or knock-
out mice were cultured for 5 days in dishes coated with immobilized Fc or CD137-Fc 
protein. Cells were then harvested and analysed by flow cytometry. Depicted are plots of 
side-scatter vs. forward-scatter. Black circles indicate the population of live myeloid cells. 
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3.5 Immobilization of recombinant CD137 protein for in vivo applications 
As well as establishing that the myeloid cells in the mouse model of AML were sensitive to 
CD137-induced differentiation, we also needed to devise a method of administering 
recombinant CD137 protein in vivo. Recombinant CD137 can only induce signalling into the 
CD137L-expressing cell when CD137L is cross-linked by immobilized CD137; soluble 
CD137 or anti-CD137L antibody is inactive (Langstein, et al 1998, Schwarz, et al 1996). 
Although this is easily achieved in vitro by coating CD137-Fc directly onto tissue culture 
plates, there are currently no practical methods for the delivery of immobilized CD137 
protein in vivo. Therefore, we briefly explored several approaches.  
5 different methods of immobilizing CD137-Fc protein were attempted. First, many 
molecules of CD137-Fc were chemically cross-linked together using the cross-linking agent, 
Dithiobis(succinimidyl propionate) (DSP), an 8-carbon chain with NHS-ester groups on both 
ends that react with primary amines to form stable amide bonds, thereby linking several 
molecules of CD137-Fc together into a larger, multimeric complex. Second, anti-Fc 
antibodies directed against the Fc-portion of CD137-Fc were used to cross-link CD137-Fc 
molecules together into a multimeric complex. Third, CD137-Fc was biotinylated and 
similarly cross-linked together using avidin. Fourth, polystyrene beads 0.6 µm or 0.8 µm in 
diameter (i.e. small enough to easily travel through capillaries) coated with Protein-G were 
used to provide a surface on to which CD137-Fc was immobilized, via the binding of Protein-
G to the Fc-portion of CD137-Fc. Fifth, freshly isolated human red blood cells were 
biotinylated (via cell surface membrane proteins) and an avidin ‘bridge’ was used to 
conjugate biotinylated CD137-Fc to the surface of the red blood cells. A schematic diagram 
of each of these methods is shown in Figure 20.  
3.5.1 CD137-Fc immobilized onto red blood cells induces IL-8 secretion and 






Figure 20. Methods for immobilization of CD137-Fc. (A) Chemical cross-linking of 
CD137-Fc using the cross-linking agent, DSP. (B) Cross-linking of CD137-Fc using anti-
Fc antibodies. (C) Cross-linking of biotinylated CD137-Fc using avidin. (D) Immobilization 
of CD137-Fc onto the surface of Protein-G-coated polystyrene beads. (E) Conjugation of 
biotinylated CD137-Fc to red blood cells using avidin. 
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5 – 10 µg of immobilized CD137-Fc protein from each of these methods was used to 
stimulate monocytes in vitro over a period of 5 days. Of these, only the fifth method, 
conjugation of CD137-Fc onto the surface of red blood cells, appeared to illicit a response. 
Immunostaining of the red blood cells expressing conjugated CD137-Fc (RBC-CD137) 
confirmed a high level of CD137-Fc present on the cell surface, while CD137 was not 
expressed on the biotinylated red blood cells (RBC-biotin) that were used as a negative 
control (Figure 21). 
Monocytes co-cultured with RBC-CD137 secreted 2-fold higher levels of IL-8 compared to 
those co-cultured with RBC-biotin. Monocytes cultured in dishes coated with CD137-Fc, 
which was used as a positive control, displayed a similar inductive response (Figure 22A). 
As reported previously (Kwajah and Schwarz 2010), monocytes treated with recombinant 
CD137 down-regulate CD14 and up-regulate CD86 expression as they differentiate into 
DCs. These immunophenotypic changes were also induced in monocytes co-cultured with 
RBC-CD137 (Figure 22B), although to a lesser extent than the positive control (Figure 
22C). Taken together, these observations indicate that CD137-Fc immobilized onto the 
surface of red blood cells is able to bind to and cross-link CD137L expressed on monocytes, 
resulting in cytokine secretion and differentiation that is characteristic of CD137L signalling in 
monocytes. 
With further optimizing of a practical and feasible method for delivering immobilized 
recombinant CD137 (or agonistic anti-CD137L antibodies) in vivo, the CD137-induced 
differentiation of AML cells in mouse models can be confirmed and, hopefully, pave the way 






Figure 21. Conjugation of CD137-Fc to surface membrane of red blood cells. Freshly 
isolated red blood cells were biotinylated, bonded with avidin, then conjugated to 
biotinylated CD137-Fc. Expression of CD137-Fc on the red blood cells was determined 
by immunostaining followed by flow cytometry. Depicted are histograms showing CD137 
expression. Open histograms show the isotype controls while the shaded histograms 






Figure 22. RBC-CD137-Fc induces changes in monocytes consistent with differentiation. 
Monocytes were cultured for 5 days with RBCs expressing conjugated CD137-Fc or 
control RBCs conjugated only with biotin, or in dishes coated with immobilized CD137-Fc 
or Fc protein. (A) The concentration of IL-8 in culture supernatants was determined by 





Figure 22 (continued). RBC-CD137 induces changes in monocytes consistent with 
differentiation. Monocytes were cultured for 5 days with (B) RBCs expressing conjugated 
CD137-Fc or control RBCs conjugated only with biotin, or in (C) dishes coated with 
immobilized CD137-Fc or Fc protein. Cells were then harvested and expression of CD14 
and CD86 were determined by immunostaining followed by flow cytometry. Depicted are 
histograms showing surface marker expression. The open profile shows isotype control 
while the shaded profiles show expression of the relevant surface markers. Numbers 
indicate the percentage of cells expressing the surface markers and the MFI. This data is 







This study has demonstrated clearly that CD137L signalling induces differentiation of 
primary acute myeloid leukaemia cells. In this section, the implications of these findings will 
be addressed. 
4.1 Previously cryopreserved AML cells are resistant to CD137-induced 
differentiation 
Consistent with previous reports that have demonstrated CD137L expression on AML cells 
and healthy myeloid cells, CD137L was detected on 9 out of the 15 cryopreserved AML 
samples tested. This surface-expressed CD137L was functional, as ligation by recombinant 
CD137 protein induced secretion of cytokines in several samples.  
Treatment with recombinant CD137, however, did not produce meaningful changes in the 
immunophenotype of any of the AML samples tested; very minor increases or decreases in 
surface marker expression were observed in a handful of samples, while the majority simply 
remained unchanged. Recombinant CD137 was therefore unable to induce differentiation of 
previously cryopreserved AML cells, despite clear expression of functional CD137L. 
The freeze-thaw process associated with cryopreservation can subject tissues to a variety of 
physical and metabolic stresses that adversely affects gene expression and mRNA 
stability/decay (Caboux, et al 2013, Shabihkhani, et al 2014). Indeed, normal peripheral 
blood mononuclear cells cultured after cryopreservation are often less viable or over-
activated (our observations). The possible dysregulation of gene expression and additional 
stresses are factors that likely contributed to the unresponsiveness of cryopreserved AML 
cells to CD137-induced differentiation. Poor viability of recovered cells was also a major 
limiting factor, as the vast majority of samples simply could not be cultured for more than 3-4 
days. The addition of survival factors, such as M-CSF or GM-CSF, may have been able to 
improve viability of the cells in vitro but would have introduced additional confounding 
elements to the investigation, as these cytokines are themselves able drive myelopoiesis. 
The use of growth factors to enhance survival was thus avoided. Cytokines such as TNF-α, 
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IL-8 and M-CSF were, however, secreted into the cultures by the AML cells themselves but 
did not appear to influence differentiation or survival in an autocrine manner, further 
illustrating the poor responsiveness of these cells. 
DMSO contained in the cryopreservation medium is itself a common myeloid cell 
differentiating agent. However, it is unlikely to have had much effect on the differentiation of 
the cryopreserved AML cells used in this study. Care was taken to quickly freeze cells that 
were suspended in the cryopreservation medium and cells were washed immediately upon 
thawing, effectively limiting contact with DMSO to a matter of minutes. Furthermore, the 
unresponsive AML cells maintained an immature immunophenotype similar to that which it 
possessed at the time of diagnosis (i.e. before cryopreservation).  
Consistent with our observations, a separate study reported that cryopreserved monocytes 
were unable to differentiate into immature DCs to the same extent as freshly obtained 
monocytes, were more resistant to maturation and cytokine secretion in response to 
inflammatory stimuli, and were less able to induce allogeneic T cell proliferation (Silveira, et 
al 2013). Taken together, this suggests that cryopreserved AML cells are an unsuitable 
candidate for the in vitro generation of dendritic-like leukaemia cells (DLLCs) – firstly, 
because they may simply not be able to acquire a DLLC phenotype and, secondly, because 
these DLLCs would be poorly immunogenic and fail in their intended roles in antigen 
presentation and stimulation of T cell-mediated anti-leukaemia responses. 
4.2 CD137L signalling induces differentiation of freshly obtained AML cells 
4.2.1 CD137-treated AML cells undergo immunophenotypic changes consistent with 
differentiation 
Unlike cryopreserved samples, freshly obtained AML cells acquired various phenotypic and 
functional changes in response to stimulation with recombinant CD137 protein. Taken 
together, these observations provide strong evidence that the cells had undergone some 
degree of differentiation. 
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One of the most straightforward and informative methods of assessing differentiation of AML 
cells is to track the expression of relevant surface markers. We found, however, that specific 
changes in surface marker profiles were not uniform or identical across all AML samples. 
Rather, the patterns of immunophenotypic change were consistent within, and dependent 
upon, the cell type and stage of myelopoiesis at which differentiation had initially become 
arrested. 
AML cells derived from very immature myeloid precursor cells, typically of the M1 and M2 
subtypes, consistently down-regulated the progenitor cell markers, CD117 and CD34, in 
response to CD137-treatment. CD11b and CD13, which are more highly expressed on 
myeloid cells of increasing maturity, were also up-regulated by these immature AML cells. 
This combination of changes indicate that CD137-treatment had induced differentiation of 
these AML cells to a more mature phenotype. 
AML cells derived from moderately mature myeloblasts of the M2 and M4 subtypes exhibited 
a pattern of immunophenotypic change that was somewhat distinct from the previous group. 
In addition to down-regulation of progenitor cell markers, up-regulation of CD14 and/or 
CD11b was strongly induced in every sample. The majority of these cells up-regulated one 
or both of the co-stimulatory molecules, CD40 and CD86, which are increasingly expressed 
in monocytes and dendritic cells. Collectively, these changes indicate that CD137-treatment 
had induced differentiation of these cells to mature, monocytic cells.  
AML cells derived from CD14+ monocytic leukaemia cells of the M5 subtype did not typically 
show substantial decreases in CD34 or CD117 expression as these were comparatively 
mature cells and were largely negative for progenitor markers. Up-regulation of CD40 or 
CD86 was also less pronounced, as these were already expressed at moderately high 
levels. In response to CD137-treatment, CD14 and HLA-DR was strongly down-regulated 
while expression of the DC marker, CD83, was increased. These changes mirror those 
observed in healthy, CD137-treated monocytes as they differentiate into DCs (Ju, et al 2009, 
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Kwajah and Schwarz 2010), indicating that monocytic AML cells also mature into dendritic-
like leukaemia cells in response to CD137-treatment. 
These observations demonstrate that the immunophenotype of AML cells follows slightly 
distinct but recognizable patterns of change, depending on the AML cell type, in response to 
treatment with recombinant CD137 protein. These immunophenotypic changes also occur 
during normal myelopoiesis of healthy myeloid cells and are indicative of the degree of 
differentiation that occurs, as generalized in Figure 23. Given that CD137-treatment induces 
differentiation of normal CD34+ haematopoietic progenitor cells to macrophages (Jiang, et al 
2008a, Jiang, et al 2008b), and that AML samples at all stages of maturity can be induced to 
differentiate, it is plausible that prolonged exposure to CD137 can drive the terminal 
differentiation of even the most immature AML cell. 
4.2.2 Monocytic AML cells acquire DC-like characteristics in response to treatment 
with recombinant CD137 
Healthy peripheral blood monocytes can terminally differentiate into either macrophages or 
DCs, depending on the biological signals received. The CD137-treated monocytic AML cells 
in this study exhibited increased co-stimulatory molecule expression, increased CD83 
expression and reduced phagocytic capacity, indicating that differentiation to DC-like cells 
was favoured. Critically, these DLLCs were able to enhance allogeneic T cell proliferation 
and secretion of pro-inflammatory cytokines, effectively demonstrating the capacity to carry 
out their functional roles in antigen presentation and mediating anti-tumour T cell responses. 
Treatment with recombinant CD137 resulted in a strong induction of pro-inflammatory 
cytokines in the vast majority of AML samples tested. Since previous reports have shown 
that cytokines such as M-CSF and TNF-α are released by monocytes upon activation with 
recombinant CD137 and act in an autocrine manner to promote survival and differentiation 
(Langstein and Schwarz 1999, Lippert, et al 2008), it is likely that the high concentrations of 




Figure 23. Schematic showing normal myelopoiesis of myeloblasts to dendritic cells with 
the associated surface marker changes, and the observed pattern of differentiation of 
AML cells in response to CD137-treatment.  
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However, it is unlikely that the observed differentiation is due solely to autocrine effects, as 
the particular cytokines secreted and their levels varied greatly between AML samples. 
Interestingly, DLLCs derived from CD137-treated monocytic AML cells did not secrete IL-12, 
a cytokine normally secreted by DCs that promotes pro-inflammatory Th1 functions in T 
cells. Nor was IL-12 secreted by any of the remaining CD137-treated AML samples. Though 
surprising, this observation is consistent with the fact that DCs generated from CD137-
treated monocytes also do not secrete IL-12 (Kwajah and Schwarz 2010). Despite the lack 
of IL-12, CD137-treated monocytic AML cells were nonetheless able to stimulate 
proliferation and IFN-γ secretion by allogeneic T cells. Several studies may help to shed light 
on this behaviour. Signal transduction through some members of the TNF superfamily, of 
which CD137L is a member, serves to counteract apoptosis via the inhibition of nuclear 
factor-κB (NF-κB) (Croft 2003). Additionally, a recent report suggests that NF-κB in DCs is 
normally required to prevent immature DCs in a ‘steady-state’ from spontaneously maturing; 
when NF-κB is lost, the DCs spontaneously mature into a unique phenotype that does not 
secrete IL-12, secretes high levels of TNF-α, and potently activates CD8+ T cells 
(Dissanayake, et al 2011). It is therefore plausible that CD137L signalling in AML cells 
inhibits NF-κB in a similar manner, thereby promoting the generation of a functional, DC-like 
phenotype that does not secrete IL-12. 
Treatment of AML cells with recombinant CD137 also augmented their migratory ability. 
Consistent with the enhanced migration observed in normal monocytes activated with 
recombinant CD137 (Drenkard, et al 2007, Kwajah and Schwarz 2010), CD137-treated AML 
cells also demonstrated an increased ability to migrate across a porous membrane. 
Acquisition of such invasive potential by solid tumours is undesirable as it promotes 
metastasis; it is, however, likely to be beneficial in AML. The enhanced migratory ability of 
CD137-treated AML cells would then facilitate migration to secondary lymphoid organs like 
the spleen and lymph nodes in a manner similar to the homing of CCR7+ DCs to these distal 
sites, where the differentiated cells can more effectively present leukaemic antigens to naïve 
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T cells, thereby improving tumour immunogenicity and initiating leukaemia-specific T cell 
responses. 
The DLLCs generated from AML cells used in this study possessed surface marker 
expression profiles that were somewhat abnormal compared to traditional DCs. HLA-DR, for 
instance, is expected to be up-regulated on traditional DCs but was instead observed to be 
down-regulated on CD137-generated DLLCs. CD14 expression in these DLLCs was also 
down-regulated to a much greater extent compared to normal DCs. This uncommon 
immunophenotype, however, is also observed in DCs derived from CD137-treated 
monocytes (Kwajah and Schwarz 2010), lending support to the notion that these 
differentiated cells are indeed DC-like and are immunophenotypically and functionally similar 
to CD137-generated DCs. These observations, as well as the lack of IL-12 or IL-23 
secretion, are also seen 
No AML samples of the M3 subtype, acute promyelocytic leukaemia, were analysed in this 
study. A remarkably effective therapy in ATRA/ATO already exists for this subtype, leading 
to excellent long term survival rates; most APL patients are now essentially curable 
(Hasserjian 2013, Wang and Chen 2008). Furthermore, CD137L signalling has been shown 
to favour monocytic differentiation and does not support granulocytic differentiation (Jiang 
and Schwarz 2010). It is therefore unlikely that treatment with a potential CD137-therapy 
would be of any additional benefit to APL patients.  
4.2.3 AML heterogeneity and sensitivity to recombinant CD137 
As previously shown in Table 5, AML samples with a variety of cytogenetic backgrounds, 
mutational statuses and FAB subtypes were assessed in this study. Of the 22 freshly 
obtained samples tested, 16 (73%) were responsive to CD137-induced differentiation. As 
only a few samples of each subtype or classification were analysed, it was not possible to 
reliably identify any associations between the level of CD137L expression, FAB subtype, 
cytogenetic or molecular abnormalities, and sensitivity to CD137-induced differentiation. 
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However, it can be noted that at least one sample from each of the M1, M2, M4 and M5 
subtypes was able to undergo CD137-induced differentiation (no M0 or M3 subtypes were 
assessed), reflecting the ability of CD137L signalling to induce differentiation in normal 
myeloid cells at various stages of myelopoiesis (Jiang, et al 2008a, Jiang, et al 2008b, 
Kwajah and Schwarz 2010, Lippert, et al 2008). 
It is not known why some of the samples were unresponsive to recombinant CD137, though 
poor viability of the AML cells may have been a contributing factor. The heterogeneity of the 
disease is also likely to have contributed to the variable responses, as the underlying 
cytogenetic abnormalities and mutations differ greatly even among responders, non-
responders and samples of the same FAB subtype. Some of these mutations may also have 
disabled important components of the CD137L signalling pathway. Nevertheless, AML 
patients who are sensitive to a potential CD137-therapy could easily be identified using the 
in vitro techniques employed in this study. It should be noted, however, that CD137L 
expression on AML cells is an unsuitable biomarker for responsiveness to CD137-therapy as 
CD137L is often difficult to detect by flow cytometry and CD137L expression did not predict 
responsiveness to CD137-induced differentiation in this study (i.e. several samples in which 
CD137L could not be detected underwent differentiation, while other samples in which 
CD137L was detected did not differentiate). 
Interestingly, the responsive Samples B4 and B22 possess the monosomy 7 karyotype, and 
Sample B12 possesses a complex karyotype of at least 3 cytogenetic aberrations. Both 
these cytogenetic profiles are associated with poorer patient outcomes (Grimwade, et al 
1998, Webb 2010), suggesting that CD137L signalling is able to induce differentiation even 
in patients with adverse karyotypes. 
4.2.4 Utility of CD137-treated AML cells in immunotherapy 
No clinically effective differentiation therapy yet exists for the treatment of AML. CD137-
treatment of AML cells may be beneficial in several respects.  
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Unchecked proliferation of immature blasts is characteristic of AML and contributes to 
disease mortality. We found that CD137-induced differentiation of AML cells was also 
accompanied by concomitant reduction in proliferation rate in vitro. Translation of both these 
effects in patients would potentially serve to slow tumour progression and contribute to a 
decrease in total number of leukaemic blasts, thereby inducing remission and improving 
overall outcomes. 
Perhaps more importantly, AML cells treated with recombinant CD137 acquire a DLLC 
phenotype. These cells, which possess increased co-stimulatory capacity and have a 
demonstrated ability to activate T cell responses in vitro, would then be able to more 
effectively present leukaemic antigens to the adaptive immune system. Recombinant 
CD137, therefore, has the potential to transform these formerly malignant, poorly 
immunogenic cells into potent initiators of anti-AML T cell responses. Such DLLCs can be 
generated in vitro from freshly obtained AML cells with the methods used in this study, and 
subsequently delivered back into the patient as a CD137-generated DLLC vaccine. This 
therapeutic approach is also advantageous in that the differentiation of even a small sub-
population of AML cells into DLLCs will be sufficient to illicit an immune response against the 
remaining population of AML cells that bear the same leukaemic antigens. This ultimately 
can lead to sustained, long-lasting and comprehensive immunogenicity that more effectively 
deals with minimal residual disease or the presence of extremely low numbers of leukaemia 
stem cells which are often responsible for disease relapse. Alternatively, recombinant 
CD137 protein or agonistic anti-CD137L can be administered directly to the patient in a 
suitably immobilized form, allowing differentiation of the AML cells to take place within the 
patient. Additional research needs to be done in this area to assess the feasibility and safety 
of this approach, and potential side effects may include non-specific induction of 
myelopoiesis/maturation in normal CD137L-expressing haematopoietic progenitor cells, 
monocytes and DCs, over-activation of CD137L-expressing macrophages possibly leading 
to macrophage activation syndrome, as well as the ‘cytokine storm’ associated with 
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widespread activation of T cells (in this hypothetical case, by immunogenic DLLCs) and 
activated CD137L-expressing cells (by the CD137-therapy) (Grupp, et al 2013, Hombach, et 
al 2013). 
Many studies have demonstrated that DLLCs can be easily generated from primary AML 
cells in vitro using various cytokine combinations. However, despite successful differentiation 
of AML cells to DLLCs that possess enhanced co-stimulatory features, these DLLCs remain 
poorly immunogenic. In one clinical trial, patients that received DLLCs subsequently had 
higher numbers of leukaemia-specific cytotoxic T cells, yet no clinical benefit was observed 
(Roddie, et al 2006). Other studies showed that DLLCs were unable even to enhance T cell 
proliferation and Th1 cytokine secretion. These DLLCs may retain some immunosuppressive 
characteristics, such as high PD-L1 expression, that continue to impair activation of T cells 
(Curti, et al 2010, Ge, et al 2009, Li, et al 2006).  
In contrast, the DLLCs generated from CD137-treated AML cells in this study were able to 
induce allogeneic T cell proliferation and IFN-γ, IL-13 and IL-17 secretion to a considerably 
greater extent compared to untreated cells. Furthermore, DCs generated from CD137-
treated monocytes are more mature than classically generated DCs and are more potent at 
stimulating antigen-specific T cell responses (Kwajah and Schwarz 2010). These 
observations suggest that CD137-generated DLLCs have superior immunogenicity 
compared with cytokine-generated DLLCs. Apart from inducing differentiation of primary 
AML cells, the use of recombinant CD137 to further mature cytokine-generated DLLCs may 
be an effective means of overcoming poor immunogenicity and sub-optimal DC function. 
Previous reports have already demonstrated that CD137L signalling induces further 
maturation of immature DCs, and that these DCs induce stronger Th1 responses compared 
to classically-matured DCs (Lippert, et al 2008). 
PD-L1 expression on the AML cells, however, was not examined in this study. Future studies 
seeking to investigate T cell-mediated cytotoxicity towards CD137-treated AML cells should 
consider the effects of PD-1 signalling in T cells. Additionally, the combination of anti-PD-L1 
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antibodies and CD137-treatment of AML cells is likely to have synergistic immunostimulatory 
effects: CD137-treated AML cells may acquire enhanced T cell activating potential while 
anti-PD-L1 antibodies block the T cell inhibitory effects of PD-L1 ligation. 
 
4.3 Transfer of CD137 to AML cells 
A recent study demonstrates that Hodgkin and Reed-Sternberg (HRS) cells, derived from 
malignant B cells that express both CD137L  and ectopic CD137 and are found in Hodgkin’s 
Lymphoma (HL), are able to transfer ectopic CD137 onto neighbouring CD137L-expressing 
HRS cells. This is dependent on the binding of CD137 expressed on the ‘donor’ HRS cells, 
to CD137L expressed on the ‘recipient’ HRS cells, after which CD137 is transferred to the 
recipient cell. This transfer results in the internalization of the CD137/CD137L complex into 
the recipient cell, effectively down-regulating surface expression of CD137L. The loss of 
CD137L expression on these HRS cells ultimately leads to impaired T cell co-stimulation, 
proliferation and IFN-γ secretion. These findings reveal a novel mechanism by which these 
malignant B cells circumvent the co-stimulatory effects that CD137L-expression normally 
confers, and effectively evade immune surveillance (Ho, et al 2013, Pang, et al 2013). 
We briefly explored whether a similar mechanism for immune evasion might be employed by 
AML cells to maintain their poorly immunogenic profile, or possibly even acquire resistance 
to CD137-induce differentiation. From our observations, AML cells do not express CD137. A 
likely cellular source of CD137 during normal physiology and, particularly, during 
inflammation is activated T cells. Indeed, we found that CD137 expressed on the surface of 
activated T cells could be transferred to healthy monocytes as well as malignant AML cells in 
as little as 2 hours. 
Using a HRS cell line over-expressing CD137 as the donor cell, we found that monocytes 
bearing transferred CD137 were less able to induce secretion of IFN-γ from allogeneic T 
cells. This suggests that transferred CD137 on the surface of antigen-presenting cells serves 
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an immunomodulatory function and reduces the ability of these cells to stimulate a T cell 
response. This suppression likely occurs via the binding of transferred CD137 to CD137L on 
the APC, blocking subsequent interaction with, and signal transduction by CD137 on the T 
cells. Consistent with these observations, previous reports demonstrate that loss of 
membrane-CD137L or blocking of the CD137-CD137L interactions between T cells and AML 
cells by antibodies or soluble CD137L diminishes subsequent T cell proliferation and 
cytokine release (Scholl, et al 2009, Vire, et al 2009). 
A short co-culture duration of no more than 2 hours was utilized so as to rule out the 
possibility of de novo synthesis of CD137 in recipient cells in response to the co-culturing of 
donor and recipient cells. Greater levels of transferred CD137 would be expected to be 
present on the recipient cells if the transfer was allowed to proceed further and a 
correspondingly greater suppression of T cell co-stimulation would also be expected.  
Recombinant CD137 protein coated onto a culture dish was also transferred to the surface 
of primary AML cells. When visualized by confocal microscopy, co-localization of both 
CD137 and CD137L was apparent within the cytoplasm of two AML samples, indicating that 
internalization of the CD137/CD137L complex had taken place. AML cells from these two 
samples demonstrated evidence of CD137-induced differentiation several days later. 
Interestingly, two additional AML samples that proved to be unresponsive to CD137-
treatment displayed only membrane co-localization of CD137 and CD137L, indicating that 
the CD137/CD137L complex was not internalized.  
Although only a small number of AML samples were analysed in this manner, it is worth 
noting that AML cells that neither differentiate nor internalize the CD137/CD137L complex 
may in fact become even more likely to escape immune surveillance, as transferred CD137 
blocks further interaction with CD137L. In AML samples that are sensitive to CD137-induced 
differentiation, internalization results in down-regulation of CD137L surface expression. 
Since this internalization takes place very soon after the initial interaction with recombinant 
CD137 (within 2 hours), it may still be possible that recycling or de novo synthesis and re-
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expression of CD137L on the surface membrane will occur, and the transient loss of 
CD137L will be of little consequence. Alternatively, differentiation of the AML cells may be 
accompanied by phenotypic down-regulation of CD137L, which may impair the ability of 
CD137-treated AML cells to effectively stimulate leukaemia-specific T cell responses, 
despite having acquired a more mature phenotype or other immunostimulatory 
characteristics. Additional research on the association between internalization of the 
CD137/CD137L complex and sensitivity to differentiation in AML would be necessary before 
further implications can be made. 
 
4.4 CD137L signalling induces differentiation of myeloid cells in a murine model of 
leukaemia 
The Cbfb knock-out mice utilized in this study as a murine model of leukaemia were 
characterized by differentiation blocks in the myeloid lineage and an expansion of the 
haematopoietic stem cell (HSC) compartment. This resulted primarily in a decreased number 
of mature myeloid cells, such as monocytes, macrophages and granulocytes in the bone 
marrow, as well as an increased number of HSCs. 
The main aim of this set of experiments was to determine the suitability of this murine model 
for use in future studies that would attempt to induce differentiation of AML in vivo. It was 
first necessary to determine if the cells in this leukaemia model were sensitive to 
differentiation by recombinant CD137 protein. Therefore, bone marrow cells were harvested 
and treated in vitro with recombinant CD137 and differentiation was assessed by observing 
changes in immunophenotype. 
Unfortunately, it was not possible to examine the effects of CD137L signalling in the 
aberrantly expanded population of HSCs, as these cells spontaneously differentiated within 
a few days of culture; even in the negative control, the vast majority of lineage-negative cells 
had lost c-Kit expression after 5 days. An attempt was also made to artificially maintain 
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stemness in vitro with the addition of stem cell factor (SCF) and IL-3 into the culture medium, 
but this was unsuccessful (data not shown). Despite this, the effects of CD137 signalling in 
the remaining bone marrow cells could be assessed. Treatment with recombinant CD137 
up-regulated the expression of CD14, CD11b, F4/80, CD86 and CD11c in the Cbfb knock-
out cells, suggesting that CD137-treatment enhanced the proportion of monocytes, 
macrophages and dendritic cells present in the cultures. Although the observed changes 
were certainly indicative of increased maturation, they were not as pronounced as those 
observed earlier with human AML samples. This is likely because a proportion of the Cbfb 
knock-out cells had spontaneously differentiated to begin with, while the remaining myeloid 
cells already displayed a moderately mature phenotype; further differentiation of these cells 
was not expected to be drastic. Interestingly, GR-1, a granulocyte marker, was the only 
surface marker that was down-regulated in response to CD137-treatment. This observation 
is consistent with the fact that CD137L signalling favours monocytic differentiation and does 
not drive granulocytic differentiation (Jiang and Schwarz 2010). 
In one experiment, CD137-treatment induced massive apoptosis in the Cbfb knock-out cells, 
but had no such effect in the healthy wild-type controls. The Cbfb knock-out cells may have 
sustained significant gene dysregulation and mutations that resulted in a particularly 
sensitive/fragile predisposition. Further stimulation by recombinant CD137 may then have 
led to activation-induced cell death.  
Because the myeloid cells in these Cbfb knock-out mice were able to differentiate in 
response to treatment with recombinant CD137, it should provide a suitable model for the 
future investigation of the in vivo effects of CD137L signalling. 
4.5 Immobilization of recombinant CD137 protein for in vivo applications 
CD137 needs to be immobilized in order to effectively cross-link CD137L and initiate 
CD137L signalling. In vitro, this is easily achieved by coating the recombinant protein directly 
onto tissue culture plates. An effective method for delivery of immobilized CD137 in vivo has 
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not yet been developed. We therefore explored several approaches in this study, and found 
some success with the conjugation of recombinant CD137 protein to the surface of red blood 
cells (RBC-CD137).  
In addition to induction of IL-8 secretion, RBC-CD137 induced down-regulation of CD14 and 
up-regulation of CD86 on monocytes, indicating that they were beginning to differentiate to 
DCs. However, these changes were less pronounced compared to those induced by plate-
bound recombinant CD137. A possible explanation is that the biotinylation of recombinant 
CD137 caused minor conformational changes to the tertiary structure of the protein, resulting 
in slightly weaker binding and cross-linking of CD137L, leading ultimately to slightly impaired 
CD137L signalling into the monocyte. Further optimization of this protocol is certainly 
required to improve the strength of the differentiating signal provided by RBC-CD137. 
RBC-CD137 provides a useful tool with which to assess the ability of CD137 to induce 
differentiation of AML cells in an in vivo setting. For clinical purposes, however, this 
approach may be unsuitable as it is time-consuming and labour-intensive. A more feasible 
alternative may be the use of polymer micro- or nano-beads, upon which a wide variety of 
proteins can be quickly and easily immobilized. Immobilization of recombinant CD137 onto 
such beads was briefly attempted in this study; for as yet unknown reasons, these CD137-
beads were ineffective at activating monocytes in vitro. Frustratingly, large quantities of 
these beads were engulfed by the phagocytic monocytes (data not shown), though it is 
unclear whether this is responsible for the ineffectiveness. Nevertheless, the use of polymer 
micro/nano-beads for drug delivery has been very successful in many other studies. With 
continued optimization, there is a good chance that a potential CD137-therapy can be 
delivered through this method.  
Although time-consuming, the immobilization and delivery of recombinant CD137 protein on 
RBCs can be an effective method for the in vivo cross-linking of CD137L expressed on AML 
cells. Blood type-matched RBCs transferred safely to the patient, while the RBC life span 
sets a natural time limit on the duration of exposure to the potential CD137-therapy. RBCs 
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can be further modified with specific antibodies to facilitate targeting to a particular site or 
cell type. CD33 is expressed on approximately 90% of AML (Lichtenegger, et al 2013). 
Conjugation of both recombinant CD137 and an anti-CD33 antibody to the RBC could 
potentially enhance targeting of these RBCs to AML cells and reduce the non-specific effects 
in other CD137L-expressing cells.  
4.6 Conclusion 
This study demonstrates for the first time that the myeloid differentiation induced by CD137L 
signalling in healthy haematopoietic progenitor cells, monocytes and dendritic cells also 
occurs in the malignant cells in acute myeloid leukaemia. CD137L signalling induces 
differentiation of primary AML cells into more mature cells that acquire various DC-like 
characteristics. This ability to overcome the maturation block in AML may prove to be 
extremely useful in potential immunotherapy and differentiation therapy of AML, as no 
clinically effective therapy for this disease currently exists. Continued investigation in this 
area is warranted, especially to further characterize the utility of CD137-treated AML cells in 
immunotherapy, and to develop an effective method of delivering this potential CD137-
therapy in vivo. 
4.7 Future work 
4.7.1 Further characterization of T cell responses to CD137-treated AML cells 
Our studies have demonstrated that CD137-treated AML cells acquire DC-like features and 
possess an enhanced ability to stimulate allogeneic T cells. It would be useful to determine 
whether these AML cells polarize the T cell-mediated immune response via preferential 
activation/differentiation of particular subsets of T cells. Indeed, there is evidence that 
CD137-generated DCs promote Th1 responses, suppress the generation of regulatory T 
cells and enhance the cytolytic activity of CD8+ T cells (Kwajah and Schwarz 2010). It would 
be especially beneficial if CD137-treated AML cells were able to enhance T cell-mediated, 
leukaemia-specific cytotoxicity while suppressing TReg activity. 
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PD-L1 is commonly up-regulated in various malignancies, including AML, and ligation with 
PD-1, expressed on T cells, effectively inhibits the anti-leukaemia T cell response. As the 
effects of PD-1/PD-L1 interactions between CD137-treated AML cells and T cells were not 
examined in this study, it would be interesting to further explore this area. The combination 
of anti-PD-L1 antibodies and CD137-treatment of AML cells may have synergistic 
immunostimulatory effects – CD137-treated AML cells can acquire enhanced T cell-
activating potential while anti-PD-L1 antibodies block the T cell-inhibiting effects of PD-L1 
ligation.  
4.7.2 Immobilization of recombinant CD137 protein or anti-CD137L antibodies 
Further efforts should be made to develop and optimize an effective means of delivering 
immobilized CD137 protein in vivo. While conjugation of biotinylated CD137-Fc to the red 
blood cell surface membrane has demonstrated efficacy, it is a time-consuming and labour 
intensive process. Immobilization of the protein or anti-CD137L antibodies to polystyrene 
microparticles, however, may prove to be a simpler and quicker approach. Microparticles 
have the advantage of being readily available in many different sizes, surface 
functionalizations (e.g. with carboxyl or amino groups) and materials and offer a high degree 
of customization. This method was briefly explored in this study but warrants continued 
investigation. However, our initial observations indicate that particle size, charge and surface 
modifications affect the likelihood of particle uptake by cells (either by phagocytosis or other 
cellular processes), which in turn leads to non-specific, pro-inflammatory responses such as 
cytokine induction and phagocytosis-induced cell death. These factors must be considered 
when optimizing the protein-microparticles for in vivo applications, as the non-specific pro-
inflammatory effects can be deleterious and overwhelm the intended effects of recombinant 
CD137 protein. 
Another approach that can be explored is the use of cell lines or transfected primary cells 
that express high levels of membrane-bound CD137. This may allow the immobilized CD137 
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protein to be presented to the AML cells in a manner that more closely resembles a 
physiological setting (for instance, on the surface of a T cell). 
4.7.3 Effects of CD137L signalling on AML cells in vivo  
After optimizing a viable method for administering immobilized CD137 protein, the effects of 
CD137 treatment should be tested in vivo to confirm the results obtained in vitro with human 
AML samples used in this study, and to establish the efficacy of the immobilized protein. The 
Cbfb conditional knock-out mice used in this study exhibited only a mild disease phenotype. 
It may therefore be worthwhile to perform future in vivo studies in a mouse model 
possessing a more profound differentiation block in the myeloid lineage, which would 
hopefully reveal a more pronounced effect in response to treatment with recombinant 
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APPENDIX 1: TISSUE CULTURE MEDIA 
 
1. RPMI 1640 (1 L) 
RPMI powder (Sigma-Aldrich)    16.35 g 
L-glutamine (200 mM) (Invitrogen)    10 mL 
Sodium bicarbonate (Sigma-Aldrich)    2.0 g 
MilliQ water       Top up to 1 L 
 
2. RPMI 1640 + 10% FBS (1 L) 
RPMI 1640       900 mL 
Fetal bovine serum (Biowest)     100 mL 
 
3. RPMI 1640 + 10% FBS + P/S (1 L) 
RPMI 1640 + 10% FBS     990 mL 





APPENDIX 2: BUFFERS FOR ISOLATION OF PBMCS 
 
1. PBS + 2 mM EDTA (1 L) 
10X PBS (1st Base)      100 mL 
EDTA (0.5 M) (1st Base)     4 mL 
MilliQ water       Top up to 1 L 
 
2. RBC lysis buffer (1 L) 
NH4Cl (Sigma-Aldrich)     8.29 g 
NaHCO3 (Sigma-Aldrich)     0.84 g 
EDTA (0.5 M)       23 µL 
MilliQ water       Top up to 1 L 
 
3. MACS buffer (1 L) 
10X PBS       100 mL 
EDTA (0.5 M)       4 mL 
0.5% BSA (Biowest)      5 g 
 
 
pH of all buffers adjusted to 7.4. 




APPENDIX 3: MISCELLANEOUS BUFFERS 
 
1. 10 mM EDTA in PBS (50 mL) 
EDTA (0.5 M)        1 mL 
10X PBS        5 mL 
MilliQ water        Top up to 50 mL 
 
2. FACS buffer (1 L) 
Fetal bovine serum       5 mL 
Sodium azide (Sigma-Aldrich)     0.2 g 
10X PBS        100 mL 
MilliQ water        Top up to 1 L 
 
 
pH of all buffers adjusted to 7.4. 
Buffers were sterile filtered through a 0.22 µm filter membrane before use. 
 
